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A B S T R A C T 
Analyzing transcriptomes in the context of all available genome and 
transcript sequence data has the potential to reveal biologically meaningful 
insight into functional properties of genes and complexity of genomes. 
Alternative splicing is one of the major mechanisms contributing to the 
complexity of genomes. This important cellular process generates several 
different messenger R N A transcripts from a single gene, expression of which 
produces structurally and functionally different proteins. Regulation of 
alternative splicing could be tissue-specific, developmental stage and/or 
physiological condition dependent. 
Comprehensive analysis of alternative splicing is essential to 
understand fully the capacity of genomes and thus proteomes. Comparative 
analyses of alternative splicing across species can provide significant 
biological insight not only to evolution of alternative splicing, but also to its 
regulation and functional significance. 
For comprehensive analyses of alternatively spliced genes, w e 
developed and utilized databases of alternatively spliced transcripts in 
transcriptomes of Homo sapiens, Mus musculus and Rattus norvegicns. Our 
databases allow in-depth analyses of alternative and constitutive exons 
within alternatively spliced genes. Interactive web implementation of our 
databases brings to end-users the ability to instantly identify orthologous 
human-mouse, human-rat and mouse-rat gene-pairs with their corresponding 
exons. A novel visualization method w e introduce, provides easy access to 
conserved alternative splicing data and a tool to explore the evolutionary 
significance, regulation and function of this important biological process. 
Our statistical analysis showed high prevalence of variant loci in 
human, mouse and rat transcriptomes. 8 1 % of human loci are variant, as are 
7 4 % of mouse loci and 5 8 % of rat loci, revealing widespread presence of 
alternative splicing in all three transcriptomes. W e further showed that 
alternative splicing events are mainly due to the presence or absence of 
cassette exons. More than 6 0 % of alternative exons are cassette exons in all 
three transcriptomes. 
Specifically, to analyze the impact of alternative splicing on 
transcription factor protein structure, w e studied the effect of cassette exons 
on protein domain architectures of mouse transcription factors. W e showed 
that alternative splicing preferentially adds or deletes domains important in 
DNA-binding function of the transcription factors. 7 5 % of the domains 
affected by cassette exons are DNA-binding domains. Further, w e showed 
that there is a single transcription factor isoform within a given tissue and 
isoforms differ across different tissues indicating tissue-specificity of 
alternatively spliced transcription factors. These results indicate that 
alternative splicing might contribute to differential gene expression via 
creation of tissue-specific transcription factor isoforms. 
In addition, w e showed that in the human transcriptome, there is a 
high prevalence of transcript sequence data from cancer tissues. More than 
8 0 % of human variant loci contain transcripts from cancer tissues. W e 
showed that cancer transcripts introduce variation beyond normal alternative 
splicing via cancer-specific cassette exons. In the majority of tissues, more 
than 2 0 % of the cassette exons are from cancer transcripts only. Our results 
quantitatively validate presence of aberrant alternative splicing in cancer 
sequence data. 
Lastly, through a comparative analysis of alternatively spliced genes in 
transcriptomes of Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis 
thaliana and Plasmodium falciparum to those in human, mouse and rat 
transcriptomes, w e showed that there is more alternative splicing in genomes 
of more complex organisms and that there is an elevation of alternative 
splicing in mammalian genomes. 
C H A P T E R 1 
I N T R O D U C T I O N 
1.1 Eukaryotic G e n e Expression, Transcription a n d Splicing 
The initial step of eukaryotic gene expression is the process of 
transcription, which involves synthesis of RNA molecules from the DNA. 
Transcribed RNA molecules are further modified via three processes called 5' 
capping, RNA splicing and 3' polyadenylation. Modified RNA molecules are 
then transported out of the nucleus for protein synthesis via a process called 
translation (Alberts et al, 4th ed.). 
Transcription is critical in that it specifies which proteins are expressed 
within a cell. Functional RNA molecules transcribed from DNA molecules are 
translated into proteins. Pre-mRNA (premature messenger RNA) processing 
determines the mRNA (mature messenger RNA) molecule's localization, 
stability and its interaction with other proteins (Cramer et al, 2001). 5' 
capping prevents degradation of the RNA molecule and enables its 
interaction with the ribosomes. 3' polyadenylation further stabilizes the RNA 
molecule (Cramer et al, 2001). 
RNA splicing is the process which removes non-coding sequences 
(introns) from the pre-mRNA molecule and ligates together the coding-
sequences (exons). Splicing takes place in the nucleus. Spliced mRNAs are 
exported out of the nucleus for protein synthesis (Alberts et al, 4th ed.). 
Splicing and transcription of RNAs are temporally and spatially coordinated 
within the cell (Cramer et al, 2001). Figure 1.1 illustrates how RNA processing 
takes place while transcription occurs. (Figure from Cramer et al, 2001). 
1.2 Alternative Splicing 
Alternative splicing is an important cellular process which generates 
several different mRNA transcripts from a single gene, increasing the 
functional complexity of genomes (Black, 2000; Brett et al, 2002). This process 
enables production of structurally and functionally different proteins. These 
proteins can range from minimal changes in function to absolutely opposite 
functions. Expression of different splice forms can be tissue-specific, 
developmental-stage and/or physiological condition dependent (Graveley, 
2001). 
Alternative splicing is thought to contribute significantly to increasing 
the complexity of human genome, given that the latest estimate of the 
number of protein coding genes in human is only 25,000 (International 
Human Genome Sequence Consortium, 2004). As of 3/1/05, the latest 
number of Ensembl gene predictions for fugu (Fugu rubripes), zebrafish (Danio 
rerio), mouse (Mus musculus) and rat (Rattus norvegicus) are 22,089, 23,524, 
28,069 and 23,751 respectively (Ensembl 2005a; 2005b; 2005c; 2005d). Fruitfly 




Figure 1.1 R N A transcription and R N A processing are temporally and 
spatially coordinated. Red line denotes D N A . Purple boxes denote exons. TF 
denotes transcription factors. Green box denotes R N A polymerase II. Small 
circles denote proteins functioning in 5' capping, splicing and 3' 
polyadenylation. Big yellow circle denotes the spliceosome. (Figure from 
Cramer et al, 2001). 
13,833 and 20,516 genes predicted by Ensembl respectively (Ensembl 2005e; 
2005f). The surprisingly low number of human genes leads biologists to 
search for mechanisms that enable complexity of our transcriptomes and 
consequently our proteomes. 
Alternative splicing is a widespread phenomenon which occurs very 
frequently within genomes. Earlier bioinformatics analyses estimated up to 
65% of the human genes to be alternatively spliced. Examples of alternatively 
spliced genes include vast majority of immune system and nervous system 
genes (Mironov et al, 1999; Modrek et al, 2001; Modrek and Lee, 2002). 
Alternative splicing of a transcript can occur in several different ways 
(Smith and Valcarcel, 2000). Figure 1.2 summarizes types of alternatively 
spliced exons. (Figure from Cartegni et al, 2002). Figure 1.2a shows a cassette 
exon which is skipped in some transcripts and is included in its entirety in 
other transcripts sequenced from the same gene. Figures 1.2b and 1.2c show 
length-variant exons with alternative 5' and 3' splice sites respectively. These 
exons are present in all transcripts sequenced from a given gene but they vary 
in nucleotide length. Mutually exclusive cassette exons are shown in Figure 
1.2d. Either one of these exons is included in a given transcript sequenced 





Figure 1.2 Types of alternative splicing. Blue boxes represent constitutive 
exons. Red and orange boxes represent alternative exons. A. Cassette exon: 
an alternative exon that is either skipped or included entirely. B. 5'-length-
variant exon: an alternative exon with alternative 5' splice sites. C. 3'-length-
variant exon: an alternative exon with alternative 3' splice sites. D. Mutually 
exclusive cassette exons: either one of these alternative exons is included in a 
given transcript. E. Intron retention: intron is retained as an alternative exon. 
(Figure from Cartegni et al, 2002). 
1.3 Evolution a n d Conservation of Alternative Splicing 
RNA splicing is thought to have originated from Group II introns with 
autocatalytic function, which are large, naturally catalytic RNAs (Ast, 2004; 
Lehman and Schmidt, 2003). The basic splicing machinery is evolutionarily 
conserved (Ast, 2004) as further discussed in Section 1.4. 
Alternative splicing is conserved across species (Thanaraj et al, 2003; 
Valenzuela et al, 2004; Yeo et al, 2005) and occurs widely in protein-coding 
genes of multicellular eukaryotes (Ast, 2004). On the other hand, unicellular 
eukaryotes such as the yeast Saccaromyces cerevisiae have not been observed to 
exhibit regulated alternative splicing (Ast, 2004). 
In human and mouse transcriptomes, both alternative exons and their 
flanking intronic sequences have been computationally observed to be 
conserved at higher levels compared to constitutive exon conservation (Sorek 
et al, 2003; Sugnet et al, 2004). Alternative exons which are protein coding 
and which do not introduce frame-shifts or premature stop codons have been 
shown to be highly conserved between species (Resch et al, 2004a). However, 
some reports show lower levels of conservation of human and mouse cassette 
exons (Nurtdinov et al, 2003). Ast and colleagues point to the similar 
sequence characteristics shared by human and mouse conserved cassette 
exons and state that conserved alternative splicing is likely to be functional 
(Sorek et al, 2004). Thus the remaining cassette exons are either species 
specific or due to aberrant splicing. 
In addition to alternative exons, splice sites tend to be conserved 
between human and mouse (Carmel et al, 2004). Majority of the mammalian 
splice junctions have canonical nucleotide sequences (Burset et al, 2000; Weir 
and Rice, 2004). 
1.4 M e c h a n i s m of Splicing a n d Alternative Splicing 
Splicing involves a network of as-acting and frans-acting factors 
(Smith and Valcarcel, 2000). Proteins of this network interact to facilitate 
splicing through two processes termed Exon Definition (ED) and Intron 
Definition (ID) (Berget, 1995). 
Splicing is catalyzed by the spliceosome complex which is composed 
of five small nuclear RNAs (snRNAs) called Ul, U2, U4, U5, U6 and as many 
as 300 other proteins (Will and Luhrmann, 1997; Nilsen, 2003). Spliceosome 
machinery recognizes exons in the pre-mRNA with high precision, removes 
introns and ligates the exons to each other forming the mature mRNA to be 
translated into proteins. Figure 1.3 illustrates assembly of the spliceosome 
proteins and RNA molecules. (Figure from Smith and Valcarcel, 2000). 
Assembly of the snRNAs with the proteins form the small nuclear ribonuclear 
protein complexes (snRNPs), which bind to the splice sites on the pre-mRNA 
molecule and facilitate removal of introns and ligation of exons (Zhou et al, 
2002; Jurica and Moore, 2003). 
(3) 5' splice site 
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Figure 1.3 Spliceosome assembly. Green circles denote hnRNPs. C B C 
denotes cap binding complex. Yellow color denotes exons. Splicing takes 
place via 5' splice site cleavage and intron lariat formation followed by 3' 
splice site cleavage and exon ligation. (Figure from Smith and Valcarcel, 
2000). 
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Four types of genomic sequence sites play important roles in intron 
splicing (Brow, 2002). These sequences, illustrated in Figure 1.4, are the 
following and they function in two transesterification reactions involved in 
intron removal. (Figure from Brow, 2002). 
(1) 5' splice site: exon-intron junction at the 5' end of the intron. 
(2) 3' splice site: exon-intron junction at the 3' end of the intron. 
(3) branch point: sequence upstream of the 3' splice site. 
(4) polypyrimidine tract: sequence between 3' splice site and branch 
site. 
In addition to conventional splicing signals, several additional splicing 
signals are involved in alternative splice site selection. Exonic Splicing 
Enhancers (ESEs), Exonic Splicing Silencers (ESSs), Intronic Splicing 
Enhancers (ISEs) and Intronic Splicing Silencers (ISSs) are short binding 
sequences for proteins which regulate alternative splicing. 
ESEs function as binding sites for a specific group of proteins called 
the SR proteins (short for serine-arginine rich proteins) (Stojdl and Bell, 1999). 
SR proteins are well conserved and contain two distinct motifs as RRMs 
(RNA recognition motifs) and the RS domain (Arginine-Serine rich domain). 
SR proteins bind to pre-mRNA via their RRM motifs and their RS domain 
mediates protein-protein interactions (Cartegni et al, 2002; Ma and He, 2003). 
SR proteins enable Exon Definition by recruiting the spliceosome to the exons 
via their RS domain. Figure 1.5a illustrates recruitment of the splicing 
machinery to ESEs on the pre-mRNA via SR proteins. In addition, SR proteins 
might function by antagonizing the effects of splicing inhibitory proteins 
which bind to ESSs neighboring ESEs as shown in Figure 1.5b. (Figure from 
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Figure 1.5 (A) Recruitment of splicing machinery to ESEs via SR proteins. 
SR protein (containing RS and R R M motifs) binds to the ESE via the R R M 
motif and recruits other splicing proteins via the RS domain. (B) Antagonistic 
effect of SR proteins to splicing inhibitors. SR protein binds to the ESE via the 
R R M motif and antagonizes the neighboring inhibitory protein which is 
bound to the ESS. Blue boxes denote exons. Black lines denote intronic 
sequences. (Figure from Cartegni et al, 2002). 
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Cartegni et al, 2002). Since SR proteins recruit the basal splicing machinery to 
the RNA, they are required both for alternative and for constitutive splicing. 
Intron Definition is carried out by several splicing proteins binding to 
the splice sites on both ends of an intron as illustrated in Figure 1.6, which 
results in removal of the intron. (Figure from Ast, 2004). SR proteins might 
mediate Intron Definition as well. 
ESSs are less well characterized compared to ESEs and their 
mechanism of action is less well understood (Cartegni et al, 2002). ESSs 
interact with negative regulators of splicing such as hnRNPs (heterogeneous 
nuclear ribonucleoproteins) (Wang et al, 2004). hnRNPs contain RNA binding 
domains as well as protein-protein interaction domains. Depending on the 
affinity and concentration of positive and negative regulators of splicing such 
as SR proteins and hnRNPs, an alternative exon can either be included or 
excluded. Silencing of splicing can also take place via ISSs. Negative splicing 
factors bind to two ISSs flanking the alternative exon on both sides. 
Interaction of the negative splicing proteins with each other while bound to 
ISSs results in skipping of the alternative exon as illustrated in Figure 1.7. 
(Figure from Cartegni et al, 2002). 
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Figure 1.6 Intron Definition. Red boxes denote exons. Gray line denotes 
intron. Circles denote splicing proteins, which are bound to splice sites on 
both ends of the intron. (Figure from Ast, 2004). 
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Figure 1.7 Cassette exon skipping via ISSs. Purple boxes denote ISSs. 
Orange box denotes the cassette exon. Blue boxes denote constitutive exons. 
Circles denote negative splicing factors bound to the ISSs. (Figure from 
Cartegni et al, 2002). 
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1.5 Regulation of Alternative Splicing 
Regulation of alternative splicing can occur in a tissue-specific, 
developmental stage and/or in a physiological condition dependent manner 
(Graveley, 2001; Woodley and Valcarcel 2002; Black, 2003). Complex 
interactions between RNA binding proteins and cis regulatory elements lead 
to tissue-specific and/or cell-specific splicing patterns (Lopez, 1998). Tissue-
specific alternative splicing plays a very important role in animal 
development. Defects in regulation of this process lead to severe human 
diseases (Grabowski and Black, 2001). 
Tissue-specificity of alternative splicing is controlled by splicing 
regulatory proteins; expression of which is restricted to certain cell types, 
such as neuron-specific splicing regulators Nova-1 and Nova-2 (Jensen et al, 
2000a; Yang et al, 1998). PTB (poly-pyrimidine-tract-binding protein) is one of 
the major proteins shown to play a role in tissue-specific alternative splicing 
(Singh et al, 1995; Valcarcel and Gebauer, 1997; Zhang et al, 1999). NAPOR 
(neuroblastoma apoptosis related RNA binding protein) is another RNA-
binding protein which regulates alternative splicing in the brain (Zhang et al, 
2002). A list of splicing regulatory proteins and their functionally important 
domains are provided in Figure 1.8. (Figure from Black, 2003). Furthermore, 
cell specific regulation could depend on regulation of splicing via different 
isoforms of a given splicing factor (Pacheco et al, 2004). To understand 
further the regulation of alternative splicing, it is essential to identify and 
analyze tissue-specific forms of alternatively spliced genes on global levels 
(Xuetal, 2002). 
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Figure 1.8 Splicing regulatory proteins. Pink boxes denote glycine-rich 
domains. Blue boxes denote R R M domains. Red boxes denote either RS or 
related domains. Yellow boxes denote glycine-rich and other specialized 
domains. Green boxes denote K H (K-homology) domains. Cyan box denotes 
R G G domain. Orange box denotes D E A D box domain. (Figure from Black, 
2003). 
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1.6 Coupling of Transcription a n d Alternative Splicing 
There is evidence indicating that alternative splicing takes place in 
coordination with transcription (Caceres and Kornblihtt, 2002). Alternative 
splicing of a gene can be dependent on the promoter region regulating the 
transcription of that gene. Figure 1.9 illustrates models explaining promoter 
regulation of alternative splicing. (Figure from Caceres and Kornblihtt, 2002). 
Different promoters might recruit different quantities of SR proteins or 
independent of the SR proteins, different promoters might enable fast or slow 
acting RNA polymerases (Cramer et al, 1997; 1999; de la Mata et al, 2003; 
Nogues et al, 2002; 2003). 
1.7 Implications of Aberrant Splicing in H u m a n Diseases 
Proper regulation of splicing is essential to healthy physiology. 
Aberrant splicing has been documented to lead to pathological conditions 
including severe diseases in humans such as osteogenesis imperfecta and spinal 
muscular atrophy (Cooper and Mattox, 1997; Schwarze et al, 1999). Defects in 
alternative splicing lead to a broad spectrum of diseases including genetic 
diseases such as Ehlers-Danlos Syndrome (Byers et al, 1997; Schwarze et al, 
1997; Takahara et al, 2002) and Occipital Horn Syndrome (Qi and Byers, 
1998). Table 1.1 shows a range of genetic disorders caused by defects in 
alternative splicing. (Data from Caceres and Kornblihtt, 2002). 
19 
(a) 






i-. ; v 
P'omcier X 
Pwi a r 
fl I I .-ffiH| 
i -i 
r u l 
(b) 
Stow pc-i II, internal pausing 
P-'ornoter X 
P™̂"**̂  *?>/&. It HUB W W I 1 
^ • " 1 . - ' .^^.r* 1 ,' 
n v Weak T Slron^ 
Promoter X 3 . ^ 3. S£ 
', I t' r' 





d r n 




,.- .A. „ 
— v J PDl III-
1 " 
Fas' po' IS, ro pausing 
Prorricler Y 
1 r n 
r -̂ "1 
Prtwiorsr V 
W e a k ' Slroncj 
V 
I V H T Z J 
- S r 7 — ' 
n 
Figure 1.9 (a) Different promoters might recruit different quantities of SR 
proteins. Promoter on the left recruits more SR proteins compared to the 
promoter on the right, (b) Independent of the SR proteins, different 
promoters might enable a slow acting R N A polymerase II (on the left) or a 
fast acting R N A polymerase II (on the right). Purple boxes denote constitutive 
exons, blue boxes denote alternative exons. Green box denotes R N A 
polymerase II, orange circles denote SR proteins. Black lines denote intronic 
sequences. (Figure from Caceres and Kornblihtt, 2002). 
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Table 1.1 Genetic disorders caused by defects in alternative splicing. 
Genetic Disorder Gene 
Acute intermittent porphyria 
Breast and ovarian cancer 
Carbohydrate-deficient glycoprotein 
syndrome type la 
Cerbrotendinous xanothomatosis 
Cystic fibrosis 
Ehlers-Danlos syndrome type VI 
Fanconi anemia 
Frontotemporal dementia (FTDP-17) 
Hemophilia A 





Neurofibromatosis type 1 
O C T deficiency 
Porphyria cutanea tarda 
Sandhoff disease 
Severe combined immunodeficiency 
Spinal muscle atrophy 
Spinal muscle atrophy 
Tyrosinemia type 1 
Porphobilinogen deaminase 
B R C A 1 

















S M N 1 
S M N 2 
Fumaryl acetoacetate hydrolase 
(Data from Caceres and Kornblihtt, 2002). 
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Aberrant splicing has been widely documented in cancers (Brinkman, 
2004; Venables, 2004; Kalnina et al, 2005). For example, alternatively spliced 
forms of cadherin-11 and Bcl-x genes have been implicated in breast and 
prostate cancers (Mercatante et al, 2001a; Feltes et al, 2002). Valcarcel and 
colleagues showed correlation of amounts of alternatively spliced isoforms of 
pl6 and pl4ARF genes with tumor formation in Hodgkin's lymphoma (Relogio 
et al, 2005). 
RNA binding proteins functioning in tissue specific regulation of 
alternative splicing, discussed in Section 1.5, are also involved in disease 
states including myotonic dystrophy, thalassemia and paraneoplastic 
opsoclonus-myoclonus ataxia (Musunuru, 2003) and cancers such as 
neuroblastoma (Palm et al, 1999). 
Several efforts are being made to correct disease states due to defects in 
alternative splicing (Sazani and Kole, 2003). Using antisense oligonucleotides, 
Kole and colleagues showed correction of cystic fibrosis transmembrane 
conductance regulator (CFTR) gene (Friedman et al, 1999). Misteli and 
colleagues showed correction of alternative splicing of tau gene implicated 
in Parkinsons and dementia (Kalbfuss et al, 2001). van Ommen and 
colleagues showed correction of dystrophin levels in Duchenne muscular 
dystrophy patients, by inducing exon skipping (van Deutekom et al, 2001). 
Given that alternative splicing has been implicated in cancers, efforts are 
being made to develop antisense oligonucleotides to control alternative 
splicing for chemotherapeutic purposes (Mercatante et al, 2001b; Mercatante 
and Kole 2002). 
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1.8 Bioinformatics a n d Alternative Splicing 
Availability of extensive full-length transcript sequences and EST data 
from genomes of different organisms enables detailed bioinformatics analyses 
of alternative splicing within and across species. Multiple sequence alignment 
approaches and DNA chip data have been used to search for evidence of 
alternative exons and to detect alternative splicing events in transcriptomes 
(Hu et al, 2001; Grasso et al, 2004; Sakai and Maruyama, 2004; Xing et al, 
2004). 
In recent years, a variety of alternative splicing databases have been 
developed based on transcript sequence data. Many of these databases have 
splice forms from one organism only, for example the Alternative Splicing 
Annotation Project (ASAP), Manually Annotated Alternatively Spliced 
Events (MAASE) and SpliceNest human databases (Coward et al, 2002; Lee et 
al, 2003; Zheng et al, 2004). Several databases contain alternative splice 
forms from two or more different organisms. These include Extended 
Alternatively Spliced EST Database (EASED) (Pospisil et al, 2004), the 
Putative Alternative Splicing database (PALSdb) (Huang et al, 2002), 
database of alternatively spliced genes (ASDB) (Dralyuk et al, 2000), an 
alternative splice database of mammals (AsMamDB) (Ji et al, 2001), database 
of canonical and non-canonical mammalian splice sites (SpliceDB) (Burset et 
al, 2001) and the Alternative Splicing Database (ASD) (Thanaraj et al, 2004). 
Bioinformatics has also been applied to comparative studies of 
alternative splicing. Given that mouse and human genes are highly conserved 
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with about 8 0 % of the mouse genes having human orthologs and more than 
90% of the human and mouse genomes being within conserved syntenic 
regions (Mouse Genome Sequencing Consortium, 2002), most of the 
comparative studies of alternative splicing focus on these two species. In a 
recent study, Kan et al. employed cross-species analyses of human and mouse 
gene sets and identified novel alternative splice forms (Kan et al, 2004). 
Sugnet et al used whole genome alignments to assess conservation of 
alternative splicing and established human-mouse conserved splicing graphs 
(Sugnet et al, 2004). As a result of a human-mouse comparative study, 
Modrek and Lee showed that alternative splicing results from exon creation 
or loss (Modrek and Lee, 2003). All of the existing alternative splicing 
databases and the cross-species comparison analyses are informative and 
facilitate further understanding of alternative splicing. In addition, efforts are 
underway to analyze alternative splicing utilizing microarray technology 
(Clark et al, 2002; Castle et al, 2003; Lee and Roy, 2004). 
In the work described here, we introduce three comprehensive 
databases of alternative splicing in human, mouse and rat transcriptomes. In 
contrast to existing databases, these bring to the end-user the ability to find 
not only the orthologous alternatively spliced genes but also their 
corresponding alternative and constitutive exons. In addition, we describe 
novel computational methods to comprehensively analyze tissue-specificity 
of alternative splicing and the effect of cassette exons on protein domain 
architecture. 
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1.9 Organization of the Thesis 
The main focus of this thesis is to answer questions about prevalence 
of alternative splicing in genomes and its effect on transcriptomes. Toward 
this goal, we developed three alternative splicing databases in human, mouse 
and rat transcriptomes as presented in Chapter 2. We utilized these databases 
to study tissue distribution of alternatively spliced mouse transcription factor 
(TF) transcripts and distribution of all variant mouse transcripts as described 
in Chapter 3. In addition in Chapter 3, we provide a detailed analysis of the 
effect of alternative exons on protein domain architecture of mouse TFs. 
Chapter 4 details pathological splicing in human cancer tissues. Chapter 5 
discusses studies of neuron-specific splicing regulator, Nova. Chapter 6 
introduces alternative splicing databases in Drosophila melanogaster, 
Caenorhabditis elegans, Arabidopsis thaliana and Plasmodium falciparum. In 
Chapter 7, we present the methods used for the above analyses. We discuss 
our findings and future directions in Chapter 8. 
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C H A P T E R 2 
U S I N G D A T A B A S E S T O A N A L Y Z E A L T E R N A T I V E 
S P L I C I N G 
2.1 Definitions 
We developed three alternative splicing databases for human, mouse 
and rat transcriptomes called HumanSDB3, MouSDB5 and RatSDB2 
respectively. H u m a n S D B 3 stands for H u m a n Splicing Database version 3; 
M o u S D B 5 for Mouse Splicing Database version 5; and RatSDB2 for Rat 
Splicing Database version 2. Methods used in developing these databases are 
described in Materials and Methods, Section 7.1. 
For the work described in this thesis, w e defined the following terms 
presented in italics. All terms are applicable to all three databases. A transcript 
is a sequence transcribed from the genomic D N A sequence and spliced. A 
locus is a genomic region that includes a set of overlapping transcripts 
mapped to the genome such that a given transcript appears only in one locus. 
Within a locus a cassette exon is completely included in some transcripts and 
completely excluded from others. A length-variant exon has alternative 5' or 3' 
splice sites or both, in different transcripts. A n exon can be both length-
variant and cassette. A variant exon is either a cassette exon or a length-variant 
exon or both. A genomic exon is an uninterrupted series of nucleotides each of 
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which maps to a transcript. A cluster is the set of transcripts that m a p to a 
locus. A variant cluster contains one or more variant exons. An invariant cluster 
has no variant exons (Taneri et al, 2004; Taneri et al, 2005). (In Chapter 1, 
Figure 1.2a illustrates cassette exons. Figures 1.2b and 1.2c illustrate length-
variant exons). Figure 2.1 illustrates the concept of a genomic exon. The 
genomic exon map of a given cluster is constructed by putting together all the 
genomic exons with intronic sequences for that cluster. 
2.2 Annotation of Alternative Exons 
There are 10 kinds of exons annotated in HumanSDB3, MouSDB5 and 
RatSDB2 as described below. These exons are annotated based on EST and 
full-length transcript sequence data as described in Materials and Methods, 
Section 7.2. 
(1) Length-invariant constitutive exon: 
a constitutive exon which has the same splice sites in all transcripts of 
a given cluster. 
(2) 5'-variant constitutive exon: 
a length-variant exon with different 5' splice sites in different 
transcripts of a given cluster. 
(3) ^'-variant constitutive exon: 
a length-variant exon with different 3' splice sites in different 






Figure 2.1 Genomic exon m a p construction. Green box denotes the 
genomic exon for a particular cluster at a particular genomic locus. Genomic 
exon starts with the leftmost nucleotide of the exon in transcript 1 (purple 
exon), it spans all of the exon in transcript 2 (yellow exon) and ends with the 
rightmost nucleotide of the exon in transcript 3 (blue exon). Genomic exon is 
the uninterrupted series of nucleotides spun by the exons in transcripts 1, 2 
and 3. 
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(4) 5' and 3'- variant constitutive exon: 
a length-variant exon which differs both at the 5' splice site and at the 
3' splice site among different transcripts of a given cluster. 
(5) Length-invariant cassette exon: 
an exon which is present in some transcripts and completely absent 
from other transcripts of a cluster. This exon has the same splice sites 
in all transcripts in which it is present. 
(6) 5'-variant cassette exon: 
a cassette exon which has varying 5' splice sites in different transcripts 
of a given cluster. 
(7) 3'-variant cassette exon: 
a cassette exon which has varying 3' splice sites in different transcripts 
of a given cluster. 
(8) 5' and 3'-variant cassette exon: 
a cassette exon which varies both at the 5' splice site and at the 3' splice 
site among different transcripts of a given cluster. 
(9) Transcript- terminal cassette exon: 
a cassette exon which is either at the 5' end or at the 3' end of the 
transcript. This exon does not map to any genomic exons of its cluster 
but rather maps to intronic regions. 
(10) Problem exon: 
an exon which is not completely mapped to the genome. 
(Cassette exons and length-variant exons are illustrated in Chapter 1, 
Figure 1.2). 
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2.3 Statistical Analyses: Variation in H u m a n , M o u s e and Rat 
Genomes 
As shown in Table 2.1, a total of 4,635,471 human, a total of 3,322,164 
mouse and a total of 552,436 rat UniGene input transcript sequences were 
used to construct the alternative splicing databases. Of these sequences 31% 
of human, 35% of mouse and 26% of rat transcripts mapped to their 
respective genomes with stringent constraints as described in Section 2.4 and 
further detailed in Materials and Methods, Section 7.1. Final versions of the 
databases contain a total of 20,707 HumanSDB3 clusters, a total of 20,090 
MouSDB5 clusters and a total of 11,330 RatSDB2 clusters. The number of 
invariant clusters in human, mouse and rat databases are 3,881, 5,221 and 
4,721 respectively. In all three transcriptomes, variant loci are in higher 
numbers than invariant loci. The number of variant clusters in human, mouse 
and rat databases are 16,826, 14,869 and 6,609 respectively (Table 2.1). 
Invariant clusters are loci with genes which do not display alternative 
splicing. Variant clusters are loci with alternatively spliced transcripts. Figure 
2.2 shows percent variation in human, mouse and rat transcriptomes to be 
81.3%, 74% and 58% respectively. These results reveal widespread presence 
of alternatively spliced genes in all three transcriptomes. Data used to extract 
these statistical information and the AutoDB database schema are further 
detailed in Chapter 7, Section 7.4 and Table 7.2. 
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Table 2.1 Statistical Analysis of HumanSDB3, M o u S D B 5 and RatSDB2 
databases. 
H u m a n S D B 3 M o u S D B 5 RatSDB2 
Total number of clusters 
N u m b e r of invariant clusters 
N u m b e r of variant clusters 
Number of input transcripts 
N u m b e r of mapped transcripts 
% of input transcripts mapped 
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Figure 2.2 Distribution of variant and invariant clusters in HumanSDB3, 
MouSDB5 and RatSDB2. Blue bars show percent variant clusters and red bars 
show percent invariant clusters in each transcriptome. Variant clusters are 
81%, 7 4 % and 5 8 % in human, mouse and rat transcriptomes, respectively. 
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The lower proportion of variation in the rat transcriptome reflects a 
lower number of rat input transcripts. Figure 2.3 shows that the percentage of 
variant clusters correlates positively with the number of input transcripts 
(Fig. 2.3a) and with the average number of transcripts within clusters (Fig. 
2.3b). 
2.4 Database Pipeline a n d Filters 
In this section, we discuss the AutoDB pipeline used in building the 
databases and provide detailed information about the number of transcripts 
rejected at each step of this pipeline. AutoDB steps are described in more 
detail in Chapter 7, Section 7.1. For HumanSDB3, we began with 4,635,471 
input transcripts. After the blat step, 8,436 transcripts were rejected (0.18% of 
input transcripts) and 4,627,035 remained. This number is only 0.27% of all 
transcripts which were rejected in total by all filters. At the SIM4 step, 625 
transcripts were rejected (0.01%) and 4,626,410 remained. This was 0.02% of 
the total rejected. After SIM4 we filtered for transcript quality. Each 
transcript had to have at least 2 exons and had to match the genome with at 
least 75% identity. Each exon had to either match the genome with at least 
95% identity or had to have 5 or fewer mismatches. At the quality filter step, 
3,150,291 transcripts were rejected and 1,476,119 remained. This was 67.96% 
of the input transcripts. This fallout constitutes 99.21% of the total fallout for 
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Figure 2.3 Percent variation in transcriptomes is positively correlated with (a) 
number of input transcripts and (b) average number of transcripts per cluster. 
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had to belong to a cluster with at least 3 transcripts in total. Transcripts 
included in singleton and doubleton clusters were dropped. At this step, 
16,153 transcripts were lost. This was 0.35% of the input transcripts and 0.51% 
of the total rejected. After the pipeline, total fallout added up to 3,175,505 
transcripts, which was 68.5% of the input transcripts. Table 2.2 shows 
numbers of human input transcripts rejected at each AutoDB filter. 
For MouSDB5, we began with 3,322,164 input transcripts. After the 
blat step, 5,784 transcripts were rejected (0.17% of input transcripts) and 
3,316,380 remained. This number is only 0.27% of all transcripts which were 
rejected in total by all filters. At the SIM4 step zero transcripts were lost. 
After SIM4 we filtered for transcript quality. Each transcript had to have at 
least 2 exons and had to match the genome with at least 75% identity. Each 
exon had to either match the genome with at least 95% identity or had to have 
5 or fewer mismatches. At the quality filter step, 2,153,688 transcripts were 
rejected and 1,162,692 remained. This was 64.83% of the input transcripts. 
This fallout constitutes 99.13% of the total fallout for the pipeline. The final 
step applied filters at the cluster level. Each transcript had to belong to a 
cluster with at least 3 transcripts in total. Transcripts included in singleton 
and doubleton clusters were dropped. At this step, 13,034 transcripts were 
lost. This was 0.39% of the input transcripts and 0.6% of the total rejected. 
After the pipeline, total fallout added up to 2,172,506 transcripts, which was 
65.39% of the input transcripts. Table 2.3 shows numbers of mouse input 
transcripts rejected at each AutoDB filter. 
For RatSDB2, we began with 552,436 input transcripts. After the blat 
step, 3,801 transcripts were rejected (0.69% of input transcripts) and 548,635 
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remained. This number is only 0.93% of all transcripts which were rejected in 
total by all filters. At the SIM4 step 11 transcripts were lost (0.002%), 548,624 
remained. This was 0.003% of the total fallout. After SIM4 we filtered for 
transcript quality. Each transcript had to have at least 2 exons and had to 
match the genome with at least 75% identity. Each exon had to either match 
the genome with at least 95% identity or had to have 5 or fewer mismatches. 
At the quality filter step, 395,624 transcripts were lost, 153,000 remained. This 
was 71.61% of the input transcripts. This fallout constitutes 96.59% of the 
total fallout for the pipeline. The final step applied filters at the cluster level. 
Each transcript had to belong to a cluster with at least 3 transcripts in total. 
Transcripts included in singleton and doubleton clusters were dropped. At 
this step, 10,169 transcripts were lost. This was 1.84% of the input transcripts 
and 2.48% of the total fallout. After the pipeline, total fallout added up to 
409,605 transcripts, which was 74.15% of the input transcripts. Table 2.4 
shows numbers of rat input transcripts rejected at each AutoDB filter. Figure 
2.4 shows that the majority of input transcripts are filtered out by the 
transcript and exon quality filter stage for all three of the transcriptomes. 
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Table 2.2 H u m a n input transcript rejection rates at each AutoDB filter. 
Stage Filter Number transcript % total transcript 
rejected rejected 
1 B L A T 8,436 0.18% 
2 SIM4 625 0.01% 
3 Transcript + Exon 3,150,291 67.96% 
Quality 
4 Cluster Quality 16,153 0.35% 
0 
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Table 2.3 Mouse input transcript rejection rates at each AutoDB filter. 
Stage Filter N u m b e r transcript % total transcript 
rejected rejected 
1 B L A T 5,784 0.17% 
0 2 SIM4 0 
3 Transcript + Exon 2,153,688 64.83% 
Quality 
4 Cluster Quality 13,034 0.39% o 
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Table 2.4 Rat input transcript rejection rates at each AutoDB filter. 
Stage Filter Number transcript % total transcript 
rejected rejected 
1 B L A T 3,801 0.69% 
2 SIM4 11 0.002% 
3 Transcript + Exon 395,624 71.61% 
Quality 




























Figure 2.4 Percent rejection rates of input transcripts by AutoDB filters. 
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2.5 Distribution of Alternative a n d Constitutive Exons 
Table 2.5 shows the distribution of alternative and constitutive exons 
in human, mouse and rat transcriptomes. The computed human, mouse and 
rat transcriptomes contain a total of 218,353, 200,274 and 138,659 exons, 37%, 
28% and 14% of which are alternative exons respectively. In all three 
transcriptomes, the majority of alternative exons are cassette exons. In 
human, 67% of alternative exons are cassette exons, as are 62% of mouse and 
62% of rat alternative exons (Fig. 2.5). As shown in Table 2.5, the majority of 
cassette exons are length invariant. In human, 77% of cassette exons do not 
vary in nucleotide length. This percentage is 82% for mouse and 93% for rat 
cassette exons. Given the fact that the majority of alternative exons are 
cassette exons, our analyses described in the following chapters focus on this 
type of variant exons. 
Length-variant exons generally vary either on the 5' end or on the 3' 
end of the exon. Very few length-variant exons vary on both the 5' and the 3' 
ends of the exon. Figures 2.6, 2.7 and 2.8 show a comparison of length-variant 
exon distribution to length-variant intron distribution. In human, in contrast 
to both 5' and 3' length variation in 7% of the exons, 68% of the introns are 
both 5' and 3' variant (Fig. 2.6). In mouse, in contrast to both 5' and 3' length 
variation in 5% of the exons, 71% of the introns vary at both ends (Fig. 2.7). 
Likewise, in rat 3% of the exons vary both at 5' and at 3' ends compared to an 
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Figure 2.5 The majority of alternative exons are cassette exons. 6 7 % of 
human, 6 2 % of mouse and 6 2 % of rat alternative exons are cassette exons. 
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(a) 
human length variant introns 
1 6 % 
1 6 % 
0 5' and 3'-variant 
• 5'-variant 
• 3'-variant 
6 8 % 
(b) 
human length variant exons 
7 % 
4 4 % H5' and 3'-variant 
• 5'-variant 
0 3'-variant 
4 9 % 
Figure 2.6 (a) Distribution of length variation in H u m a n S D B 3 introns. (b) 
Distribution of length variation in H u m a n S D B 3 exons. 
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(a) 
mouse length variant introns 
1 5 % 
1 4 % 35' and 3'-variant 
• 5'-variant 
3 3'-variant 
7 1 % 
(b) 
mouse length variant exons 
5 % 
4 5 % 15' and 3'-variant 
• 5'-variant 
ZI3'-variant 
5 0 % 
Figure 2.7 (a) Distribution of length variation in M o u S D B 5 introns. (b) 
Distribution of length variation in MouSDB5 exons. 
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(a) 
rat length variant introns 
1 1 % 
8 % 




rat length variant exons 
3 % 
4 6 % 
1 5 1 % 
5' and 3'-variant 
5'-variant 
3'-variant 
Figure 2.8 (a) Distribution of length variation in RatSDB2 introns. (b) 
Distribution of length variation in RatSDB2 exons. 
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than an exon-centric regulation of length variation in alternative exons. If 
length variation was controlled in an exon-centric manner, then distribution 
of 5' and 3' length variation in introns should have been lower or similar in 
numbers compared to the same distribution in exons. 
2.6 Transcript Terminal Exons 
We observed a specific subset of cassette exons present either at the 5' 
or at the 3' ends of transcripts, which do not map to any genomic exons of the 
clusters they are present in. These exons rather map to intronic regions. We 
termed these exons as transcript-terminal cassette exons to distinguish them 
from the internal cassette exons discussed in Section 2.5. 
Transcript-terminal cassette exons occur in high numbers in human, 
mouse and rat transcriptomes. Table 2.6 provides statistics of occurrences of 
transcript-terminal cassette exons in HumanSDB3, MouSDB5 and RatSDB2. 
Figure 2.9 shows that transcript-terminal cassette exons are widely present in 
all three transcriptomes. In human, 30% of all cassette exons are transcript-
terminal. In mouse and rat these percentages are 32% and 26% respectively. 
Transcript-terminal cassette exons elevate alternative exon numbers by 22% 
in human, 22% in mouse and 18% in rat transcrioptomes. In addition, we 
show that in 1234 of human variant clusters, 1475 of mouse variant clusters 
and 817 of rat variant clusters, variation is due to transcript-terminal cassette 
exons. These constitute 7% of all variant clusters in human, 10% of all variant 
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Figure 2.9 Prevalence of transcript-terminal cassette exons in h u m a n , 
m o u s e and rat transcriptomes. Blue bars denote h u m a n alternative exons. 
Red bars denote m o u s e alternative exons. Yellow bars denote rat alternative 
exons. Percentage of internal cassette exons are highest in all three 
transcriptomes. Transcript-terminal cassette exons are almost as prevalent as 
length-variant exons. Transcript-terminal exons elevate the alternative exon 
numbers in h u m a n by 2 2 % , in mouse by 2 2 % and in rat b y l 8 % respectively. 
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% of all variant 
clusters 
human mouse 
Figure 2.10 Variant clusters due to transcript-terminal cassette exons. 7 % of 
human variant clusters, 1 0 % of mouse variant clusters and 12% of rat variant 
clusters are variant due to presence of transcript-terminal cassette exons. 
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Our analysis showed for the first time high prevalence of transcript-
terminal cassette exons in human, mouse and rat transcriptomes. These 
exons are either due to noise in the sequence data or they might be due to 
relatively rare transcription events such as alternative initiation or 
termination of transcription (Zavolan et al, 2003). 
In our alternative splicing analyses, presented in the following 
chapters, we focus only on internal cassette exons to minimize aberrant 
splicing in the data. Our results indicate that it is important to consider 
differences between transcript-terminal and internal cassette exons in future 
analyses of alternative splicing. 
2.7 Graphical User Interfaces of Alternative Splicing Databases 
HumanSDB3, MouSDB5 and RatSDB2 alternative splicing databases 
can be browsed through web-based graphical user interfaces. AutoDB hosts 
all three databases at http: / / genomes.rockefeller.edu / autodb / sdb.php (also 
available at http: / /sgc.ucsd.edu / autodb/sdb.php). HumanSDB3 can be 
accessed at 
http:/ /genomes.rockefeller.edu/autodb/sdb.php?db=HumanSDB3 (also 
available at http: / /sgc.ucsd.edu/ autodb /sdb.php?db=HumanSDB3), 
MouSDB5 can be accessed at 
http:/ /genomes.rockefeller.edu/autodb/sdb.php?db=Mou5DB5 (also 
available at http:/ /sgc.ucsd.edu/autodb/sdb.php?db^MouSDB5) and 
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RatSDB2 can be accessed at 
http: / / genomes.rockefeller.edu/autodb /sdb.php?db=RatSDB2 (also 
available at http: / /sgc.ucsd.edu/autodb/sdb.php?db=RatSDB2). 
Web implementations of the databases provide access to each variant 
and invariant splicing cluster along with database statistics. Through these 
interfaces, users can access database statistics on transcripts, chromosomes, 
clusters and exons. When available, annotation and library information for 
each transcript are provided. Nucleotide sequences of each alternative and 
constitutive exon are also given. Splice clusters can be accessed by providing 
as input any of the following parameters of the user's gene of interest: 
annotation, chromosome number, cluster ID, cluster type or UniGene ID. 
Figures 2.11, 2.12 and 2.13 show screenshots of variant HumanSDB3, 
MouSDB5 and RatSDB2 clusters respectively. Figure 2.11 shows HumanSDB3 
variant cluster representing human general transcription factor IIB. Figure 
2.12 shows MouSDB5 variant cluster representing mouse general 
transcription factor IIB. Figure 2.13 shows RatSDB2 variant cluster 
representing rat general transcription factor IIB. Web implementation of the 
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2.8 C o m p a r e Species Feature of the Databases 
This section introduces the interactive web implementation of our 
databases which allows queries by the end-user to compare orthologous 
alternatively spliced gene-pairs. Figure 2.14 shows the flowchart of this 
feature for HumanSDB3 and MouSDB5 orthologous cluster comparison. Our 
Compare Species feature allows the end-user to compare any two orthologous 
transcripts and their corresponding exons. As shown in Figure 2.15, our 
program aligns the human and mouse genomic exon maps. Lines going 
across the opposite exons indicate the orthologous human-mouse exons. In 
this figure, top line represents the genomic exon map for human general 
transcription factor IIH and bottom line represents the genomic exon map for 
the orthologous mouse general transcription factor IIH. 
The Compare Species feature of HumanSDB3 and MouSDB5 databases 
can be accessed at 
http:/ /genomes.rockefeller.edu/autodb/compare l.php?dbl=HumanSDB3 
&db2=MouSDB5 (also available at 
http:/ /sgc.ucsd.edu/autodb/compare l.php?dbl=HuirtanSDB3&db2=MouS 
DB5). End-users are able to find their gene-pair of interest by providing as 
input any of the following parameters: Keyword, Gene Symbol, Splicing 
Cluster ID, GenBank accession number or UniGene cluster ID. This feature is 
also available for orthologous human-rat and orthologous mouse-rat genes. 
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| H u m a n S D B 3 
h u m a n variant 
clusters 
A u t o D B 
M o u S D B S 
m o u s e variant 
clusters 
Extract J G E Extract J G E 
o r t h o l o g o u s clusters 
o r t h o l o g o u s e x o n s 
Figure 2.14 Flowchart of Compare Species Feature of the databases. Joined-
genomic exons (JGEs) from variant clusters of H u m a n S D B 3 and MouSDB5 
are utilized to establish orthology of human-mouse gene pairs. 
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Database of Splicing Variants. Comparison of Hs.3.chr5n.15596 and 
Mm.5.chrl3n.4377. 
Hs. 191356: General transcription factor IIH, polypeptide 2, 44kDa 
M E length-invariant constitutive 
8MB 5'-varlant constltutlve 
HB3'-variant constitutive 
U W i ' - 8, ^'-variant constitutive 
KB!"problem" e/on (unmapped or partially mapped to genome) 
aaAa-ra genomic map intron 
MRI length-invariant raisette 
'. • ̂ '-variant cairette 
3'-vanant catrette 
i-".-.5'- I 3'-variant cassette 
IBQexon? containing COS 







Figure 2.15 Comparison of exons in an orthologous human-mouse gene 
pair for general transcription factor IIH, polypeptide 2. Top line represents 
genomic exon m a p of human variant cluster Hs.3.chr5n.l5596. Bottom line 
represents genomic exon m a p of mouse variant cluster Mm.5.chrl3n.4377. 
Orthologous exons are indicated by lines going across from the two genomic 
exon maps. 
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H u m a n S D B 3 and RatSDB2 comparison feature can be accessed at 
http: / / genomes.rockefeller.edu/ autodb / compare 1 ,php?dbl=HumanSDB3 
&db2=RatSDB2 (also available at 
http: / /sgc.ucsd.edu/autodb/compare 1 .php?dbl=HumanSDB3&db2=RatS 
DB2). MouSDB5 and RatSDB2 comparison feature can be accessed at 
http: / / genomes.rockefeller.edu/ autodb /compare 1 .php?dbl=MouSDB5&:d 
b2=RatSDB2 (also available at 
http://sgc.ucsd.edu/autodb/compare l.php?dbl=MouSDB5&db2=RatSDB2 
). Development of the Compare Species feature is further described in Materials 
and Methods, Section 7.6. 
2.9 Discussion 
The databases presented here provide a comprehensive overview of 
alternative splicing events in human, mouse and rat transcriptomes. These 
databases identify, classify, compute, store and answer queries about splice 
variants within these three transcriptomes. They provide the user with 
information about all transcripts that map to a certain genomic locus. 
Complete sequences of transcripts, their annotations and when available the 
tissues from which they are sequenced from are provided. All exons of each 
transcript within a cluster are annotated as alternative or constitutive and 
their sequences are provided as links. 
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Our databases enable detailed computational analyses of alternative 
splicing. In addition, our databases open up possibilities for experimental 
design to further study alternative splicing on a single gene level or at 
more global levels. The Compare Species feature of these databases allows 
users to view genomic maps of orthologous alternatively spliced genes in 
pairs. Users can visualize the orthologous gene structures and their 
corresponding exons. This information is readily accessible and along with 
our novel visualization tool, it facilitates easy comparative analysis of 
alternative splicing and allows studies of evolution of this important cellular 
process. 
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C H A P T E R 3 
A L T E R N A T I V E S P L I C I N G O F M O U S E T R A N S C R I P T I O N 
F A C T O R S 
3.1 Introduction to Transcription, Transcription Factors a n d 
G e n e Expression 
As introduced in Chapter 1, transcription is a critical process which 
specifies m R N A s and thus proteins expressed within a cell. R N A 
polymerases, enzymes which catalyze transcription, bind to promoter 
sequences and move along the D N A template until they reach a stop codon. 
In addition to R N A polymerases, transcription requires many other proteins 
including transcription factors (TFs). Transcription factors help R N A 
polymerase bind to the regulatory sequences on D N A and facilitate 
transcription (Alberts et al, 4th ed.). 
Expression of a given gene is dependent on the interactions of different 
transcription factors and their cofactors with the regulatory regions of that 
gene. Different transcription factors regulate transcription in different ways. 
Transcription factors in turn are regulated by several processes which include 
interaction with other proteins and signaling cascades (Lopez, 1995). As 
discussed in Section 1.6, alternative splicing is thought to occur in 
coordination with transcription (Caceres and Kornblihtt, 2002). In this 
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chapter, w e describe a detailed study of alternative splicing of mouse 
transcription factors. 
3.2 Regulation of Transcription Factors b y Alternative Splicing 
Alternative splicing is one of the mechanisms that regulates 
transcription factor activity. As noted by Lopez, alternative splicing can affect 
TF protein structure in two primary ways (Lopez, 1995). Alterations can be in 
the DNA-binding domains of TFs, affecting their affinity or specificity for 
regulatory regions on the DNA; or alterations can modulate interactions of 
TFs with their cofactors (Latchman, 2001). Such changes have been observed 
experimentally to alter specificity or binding strength or to switch between 
activator and repressor isoforms of the same transcription factor (Foulkes and 
Sassone-Corsi, 1992). For example, the cAMP-response element modulator 
has three different isoforms with entirely different DNA-binding domains, 
which are all transcription activators. On the other hand, isoforms of the 
human transcription factor AML1 function both as positive and as negative 
regulators of transcription (Lopez, 1995). 
We used MouSDB3 (a prior release of MouSDB5), a database of mouse 
alternatively spliced transcripts, to study alternative splicing of transcription 
factors. As shown in Figure 3.1, in MouSDB3 out of the 461 TF clusters, 62% 








variant clusters (62%) 
H invariant clusters (38%) 
Figure 3.1 Cluster Analysis of Mouse Transcription Factors. Out of a total 
of 461 Transcription Factor clusters in MouSDB3, 287 are variant and 174 are 
invariant. 
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3.3 Tissue Distribution of Alternatively Spliced Transcription 
Factor Transcripts 
We analyzed tissue distribution of alternatively spliced transcription 
factors in 18 tissues chosen from the existing libraries in MouSDB3. These 
tissues are chosen because they contain both variant and invariant transcripts 
annotated as TFs. To account for library ambiguities, libraries which list 
several tissues or cell types for a single entry such as mixture of brain and testis 
and libraries which provide no tissue information at all such as embryo or 
carcinoma are screened out. In addition, for some tissues, several parts of a 
given tissue are pooled into one term. For example, the term brain 
corresponds to all parts of the brain found in MouSDB3 libraries, including 
cerebellum, thalamus, hippocampus and 16 other libraries. Methods used for 
the tissue distribution analysis are described in Chapter 7, Section 7.7. 
As shown in Figure 3.2a, our comparative analysis revealed that in 14 
out of the 18 tissues analyzed, the proportion of TFs that are variant is higher 
than the proportion of all genes that are variant. Eight tissues exhibited more 
than two-fold differences in variant TFs versus variant genes in total (Fig. 
3.2b). Note that values in Figure 3.2b are base 2 logarithms of the ratios. 
Tissues with more than two-fold differences have log2 values above 1 on the 
graph. In salivary gland, skeletal muscle, urinary bladder and testis, the fold-
differences are 8.7, 5.6, 3.8 and 3.0-fold respectively. These tissues are 
followed by spinal cord, liver, adipose tissue and eye which also exhibit more 
than two-fold differences. 
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Figures 3.3 and 3.4 show that the values of fold-differences shown in 
Figure 3.2b are independent of sampling depth of the transcripts from these 
tissues. Sampling depth is the total number of transcripts sequenced per 
tissue. Figures 3.3a and 3.4a display absolute numbers of variant TF 
transcripts and absolute numbers of the entire variant transcripts of the 
transcriptome per given tissue respectively. The correlation coefficient of the 
absolute number of TFs and the fold-differences between variant TFs and all 
genes is -0.13, indicating that they do not correlate. Likewise, the correlation 
coefficient of the absolute number of all genes and the fold-differences 
between variant TFs and all genes is -0.46. In addition, the scatter-plots in 
Figures 3.3b and 3.4b show that there is no correlation between the sampling 
depth and the fold-differences. These results indicate that TFs exhibit higher 
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Figure 3.3 Fold-differences are independent of sampling depths of 
transcripts from given tissues, (a) Absolute n u m b e r of variant TF 
transcripts per tissue, y-axis: n u m b e r of variant TF transcripts; x-axis: 
tissues, (b) For each tissue; x-axis: ratio of variant TF transcripts to all 
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Figure 3.4 Fold-differences are independent of sampling depths of 
transcripts from given tissues, (a) Absolute number of all variant 
transcripts per tissue, y-axis: number of all variant transcripts; x-axis: 
tissues, (b) For each tissue; x-axis: ratio of variant TF transcripts to all 
variant transcripts; y-axis: absolute number of all variant transcripts. 
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3.4 Homogeneity-Heterogeneity of Isoforms 
To study tissue-specificity of alternatively spliced TF isoforms and 
other mouse genes, we defined four terms presented below in italics and 
further described in Materials and Methods, Section 7.7. 
(1) homogeneity within tissues: all transcripts sequenced from the same tissue 
have cassette exons with same splice sites (Fig. 3.5). 
(2) heterogeneity within tissues: transcripts sequenced from the same tissue 
have cassette exons with different splice sites (Fig. 3.6). 
(3) homogeneity across tissues: transcripts sequenced from different tissues have 
cassette exons with same splice sites (Fig. 3.7). 
(4) heterogeneity across tissues: transcripts sequenced from different tissues 
have cassette exons with different splice sites (Fig. 3.8). 
We used the ratio of homogeneity-heterogeneity to assess tissue 
specificity. To determine the homogeneity-to-heterogeneity ratios of isoforms 
within the 18 tissues studied, we analyzed the presence of different isoforms 
of TFs within and across these tissues. Differences between isoforms were 
established based on splice sites of cassette exons within the coding 
sequences of transcripts. Variations due to 5' and 3' truncations of transcripts 
were not counted. 
As shown in Figure 3.9, when heterogeneity-to-homogeneity ratios are 
compared within and across tissues, there is significantly higher 
heterogeneity of isoforms across tissues than within a single tissue (p-value = 
0.04). This is true both for variant transcription factors and for all the variant 
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genes in the mouse transcriptome. W h e n single tissues are taken into account, 
TFs are more homogeneous within each tissue analyzed (Fig. 3.10). 
Heterogeneity to homogeneity ratios in all tissues are lower than 1, indicating 
homogeneity of TF isoforms within these tissues. When all genes are 
considered, heterogeneity to homogeneity ratios are also below 1, indicating 
homogeneity of isoforms of all variant genes within these tissues. However, 
TFs are significantly more homogeneous within a given single tissue when 
compared to all genes (p-value = 0.02). These findings indicate that the 
majority of TF isoforms and isoforms of all alternatively spliced genes differ 
across tissues; whereas, within a given single tissue there generally is only 
one isoform. 
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| f | 
1 § H 
Figure 3.5 Homogeneity of Isoforms Within Tissues. Within this variant 
cluster all liver transcripts have the same cassette exon splice sites (i.e. they 
are all the same isoform). Pink boxes denote the cassette exons. Other boxes 
denote constitutive exons. Red lines denote intronic sequences. This cluster is 
considered to be homogeneous within liver. 
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Figure 3.6 Heterogeneity of Isoforms Within Tissues. Within this variant 
cluster different spleen transcripts have different cassette exon splice sites (i.e. 
they are different isoforms). Pink box denotes the cassette exon. Blue and 
green boxes denote constitutive exons. Red lines denote intronic sequences. 
This cluster is considered to be heterogeneous within spleen. 
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Figure 3.7 Homogeneity of Isoforms Across Tissues. Within this variant 
cluster, all heart transcripts and all m a m m a r y gland transcripts have the same 
cassette exon splice sites (i.e. they are all the same isoform). Pink box denotes 
the cassette exon. Red lines denote intronic sequences. This cluster is 
considered to be homogeneous across heart and mammary gland. (For a cluster to 
be considered homogeneous across tissues, all tissues studied have to have 
the same cassette exon splice sites and for an across tissue comparison, the 
cluster has to be homogenous within all tissues analyzed.) 
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(a) Liver specific isoform: 
EiXSi' nSlf ) i ,ji-\ 
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(o) Brain specific iscform: 
BI»»449i n, .-.,-<• i I* 
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cassette axon 
Figure 3.8 Heterogeneity of Isoforms Across Tissues. Within this variant 
cluster, liver transcripts and brain transcripts have different cassette exon 
splice sites (i.e. they are different isoforms). Pink boxes denote the cassette 
exon. Other boxes denote constitutive exons. Red lines denote intronic 
sequences. This cluster is considered to be heterogeneous across liver and brain. 
(For a cluster to be considered heterogeneous across tissues, at least one of the 
tissues studied has to have different cassette exon splice sites and all tissues 
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Figure 3.9 Isoforms of alternatively spliced genes are more homogeneous 
within single tissues than across different tissues. Blue bars represent ratio of 
number of TF clusters with multiple isoforms within a given tissue to number 
of TF clusters with only a single isoform within that tissue. Red bars represent 
ratio of number of all variant clusters with multiple isoforms within a given 






Figure 3.10 Distribution of heterogeneity versus homogeneity of isoforms 
within single tissues. Blue bars represent ratio of TF clusters with multiple 
isoforms within the given tissues to TF clusters with only a single isoform 
within that tissue. Red bars represent ratio of all variant clusters with 
multiple isoforms within the given tissue to variant clusters with only a single 
isoform within that tissue. Tissue abbreviations; M G : m a m m a r y gland, SM: 
skeletal muscle, SC: spinal cord. 
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3.4 Effect of Cassette Exons o n Transcription Factor Protein 
Domain Architecture 
Analyzing proteins in the context of all available genome and 
transcript sequence data has the potential to reveal functional properties not 
accessible through protein sequence analysis alone. Alternative splicing has 
been shown to alter domain architectures of proteins (Kriventseva et al., 2003; 
Liu et al, 2003; Cline et al, 2004; Resch et al, 2004b). To analyze the impact of 
alternative splicing on transcription factor protein structure, we screened 287 
variant TF loci within MouSDB3 (a prior release of MouSDB5) for the 
presence of cassette exons within coding sequences. As shown in Figure 3.11, 
the 287 variant TF loci contain a total of 324 cassette exons, of which 23% (76 
exons) are in-frame and in codon position 1. Only 11% of the cassette exons 
are expected to be multiples of three and in codon position 1 randomly. The 
two-fold difference between expected and observed numbers indicates a bias 
towards presence of in-frame cassette exons. 
Of the transcripts containing the 76 in-frame cassette exons, 66 had 
domain architectures predicted by SMART (Ponting et al, 1999; Letunic et al, 
2002; 2004). SMART is a search tool for domain architectures and can be 
accessed at http: / / smart.embl-heidelberg.de /. 80% (53 exons) of these exons 
induced a domain structure alteration when skipped. Of these 53 structure-
altering exons, 68% (36 exons) were within coding regions for domains that 
are important for TF activity. The remaining 32% (17 exons) were proximal to 
the computed domain boundaries (Fig. 3.11). When the cassette exon was 
78 









| no domain architecture ( with domain architecture 
* predicted by S M A R T 
: 13 | 




outside of domains i ; within a domain 
36 
Figure 3.11 M o u s e transcription factor cassette exon analysis. 287 variant T F 
clusters have a total of 324 cassette exons. W h e n 76 of the 324 cassette exons 
are skipped, the altered transcripts are in-frame. Exclusion of remaining 
exons either introduces an amino-acid substitution or causes frame-shifting. 
O f the in-frame exons, 53 alter d o m a i n architecture and 13 d o not. O f the 
exons that cause d o m a i n alteration, 36 are in coding regions for domains and 
17 are proximal to the coding regions. 
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removed, the sequence no longer met the computational criteria for the 
domain. 
Figure 3.12 illustrates loss of a zinc finger domain detected by SMART 
due to deletion of an in-frame cassette exon. Top panel illustrates the 
transcript, denoted as the original transcript, with the cassette exon which 
codes for a basic leucine zipper domain and a zinc finger domain shown on 
the right. Bottom panel illustrates the transcript, denoted as the altered 
transcript, which skips the cassette exon. This transcript codes only for the 
basic leucine zipper domain and is missing the zinc finger domain (shown to 
the right of the transcript). 
SMART (Schultz et al, 1998; 2000) and Pfam (Bateman et al, 2002; 2004) 
annotations of the altered domains revealed that 75% of the domains affected 
by alternative splicing with known functions are DNA-binding domains. 
Pfam is a database of protein families and can be accessed at 
http://vyww.sanger.ac.Uk/Sofi:ware/Pfam/index.shtml. Figure 3.13 provides 
homeobox domain annotation as an example of a DNA-binding domain. 
Figure 3.14 shows a partial list from the web-page which displays the 
annotation of transcripts containing domains altered by cassette exons. Links 
to domain annotations and to GenBank entries for the transcripts are 
provided on this page. The full list can be accessed at 
http: //genomes.rockefeller.edu/~bahar/TF.html (also available at 
http: / /sgc.ucsd.edu/ -bahar /TF.html). Sequences of cassette exons can also 
be downloaded in forms of fasta files. Nucleotide and amino acid sequences 
of the original and the altered transcripts are also provided as fasta files. 
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Figure 3.12 Deletion of in-frame cassette exon, indicated by the arrow, leads 
to loss of detection of zinc finger domain by S M A R T . Top left panel shows the 
original transcript, bottom left panel shows the altered transcript. Right 
panels show protein domains coded by these transcripts. 
denotes basic region leucine zipper; s £ denotes zinc finger C2H2 
and «m denotes low complexity regions."""' 
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Methods used in this analysis can be found in Chapter 7, Section 7.8. 
Appendix A provides a full list of domains altered by cassette exons along 
with GenBank ids for transcripts and variant exon numbers. 
3.6 Discussion 
In this work, we show that the majority of TF isoforms and isoforms of 
all alternatively spliced genes differ across tissues. Further, we show that 
within a given single tissue there generally is only one isoform. These 
findings suggest that alternative splicing creates tissue specific isoforms of 
TFs and thus can contribute to regulation of gene expression in a tissue 
specific manner. 
Given the finding that in 78% of the tissues studied, TFs display higher 
proportions of variation compared to proportions of all genes in these tissues 
and the finding that 62% of all TF loci are variant, indicate the widespread 
impact of alternative splicing on regulation of gene expression via different 
TF isoforms. 
In addition, the study presented here provides quantitative evidence 
that alternative splicing preferentially adds or deletes domains important to 
the DNA-binding function of TFs via inclusion or exclusion of in-frame 
cassette exons. 
We provide quantitative evidence for structural and functional 
significance of variant exons in control of transcription and regulation of gene 
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expression by alternative splicing via creation of tissue-specific TF isoforms. 
The work described here implies that future high-throughput screens of gene 
expression analyses should be sensitive to multiple alternatively spliced 
forms of TFs. Because gene expression arrays are intended to measure 
transcription, the next generation of arrays should contain probes specific to 
all known isoforms of genes represented on the arrays. In addition, this study 
opens up possibilities of detailed analysis of other groups of proteins which 
are widely affected by alternative splicing. 
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C H A P T E R 4 
P A T H O L O G I C A L S P L I C I N G I N C A N C E R T I S S U E S 
4.1 Introduction 
Given that aberrant splicing has been widely documented in cancer 
cells and cancer tissues (Brinkman, 2004; Hui et al, 2004; Venables, 2004; 
Kalnina et al, 2005), we investigated the degree to which cancer ESTs add 
variation beyond normal alternative splicing. For this analysis, we used 
HumanSDB3, a database of alternative splicing in human transcriptome, 
which contained a total of 361 DNA sequence libraries from cancer related 
tissues and cells. Methods used for this analysis are described in detail in 
Chapter 7, Section 7.9. 
4.2 Definitions 
For this study, we defined the following terms presented in italics. 
Normal-only clusters contain transcripts from normal tissues only. Cancer-only 
clusters contain transcripts from cancer tissues only. Mixed clusters contain 
transcripts both from normal tissues and from cancer tissues. Potentially 
pathological clusters comprise cancer-only clusters and mixed clusters. 
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4.3 Extent of Cancer Transcripts in H u m a n Transcriptome Data 
Figure 4.1 illustrates the distribution of normal and cancer transcripts 
within human variant clusters. 13% of human variant clusters contain 
transcripts from normal tissues only. 14% of human variant clusters contain 
transcripts from cancer tissues only. The remaining 73% of clusters contain a 
combination of transcripts both from normal and from cancer tissues. 
Figure 4.2 shows the same values within each tissue. All tissues 
studied have more than 80% of their clusters to have cancer transcripts with 
the exception of prostate for which this number is 73%. These clusters either 
contain all cancer transcripts or are a mixture of normal and cancer 
transcripts. For breast, brain, colon, lung, kidney, skin and ovary more than 
10% of clusters are completely cancer-only (Fig. 4.3). These numbers are 
exceptionally high for ovary and skin at 67% and 47% respectively. Taken 
together, these results underscore the high prevalence of transcript sequence 
data from cancer tissues in the human transcriptome. 
4.4 Distribution of Cassette Exons in N o r m a l versus Cancer 
Clusters 
In our analyses described in previous chapters, we used the presence 
and absence of cassette exons to determine distinct splice isoforms. We 
investigated the average number of cassette exons in normal versus cancer 
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Figure 4.1 Distribution of normal and cancer transcripts within human 
variant clusters. 14% of clusters contain transcripts from normal tissues only. 
13% of clusters contain transcripts from cancer tissues only. 73% of clusters 
contain a combination of transcripts both from normal and from cancer 
tissues. 
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Figure 4.2 Distribution of human variant clusters across tissues. Purple 
bars denote sum of cancer-only and mixed clusters i.e. potentially 
pathological splicing clusters. Blue bars denote normal-only clusters, y-axis: 

























Figure 4.3 Distribution of human variant clusters with cancer, normal and 
mixed transcripts across tissues, y-axis: percentage of clusters. Tissues are 
ordered by sum of cancer only and mixed clusters, in descending order. 
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transcript-containing variant clusters. With the exception of thymus, the 
remaining 11 tissues contained transcripts from both normal-only and 
cancer-only clusters, as seen in Figure 4.3. When analyzed across these tissues, 
there is no significant difference in overall average numbers of cassette exons 
between normal-only and cancer-only clusters (p-value = 0.516). Likewise, 
there is no significant difference in overall average numbers of length-variant 
exons between normal-only and cancer-only clusters (p-value = 0.489). 
4.5 Splicing in N o r m a l versus Cancer Tissue Isoforms 
We investigated the cassette exons within HumanSDB3 variant 
clusters which contain both cancer and normal transcripts, i.e. the mixed 
clusters as defined in Section 4.2. We wanted to assess the differences 
between normal and cancer transcripts based on cassette exon splice sites. 
Our global level cluster analysis revealed that 5.75% of the cassette exons are 
exclusive to cancer transcripts only and 2.43% of the cassette exons are 
exclusive to normal transcripts only. The remaining 91.81% of cassette exons 
are common to both normal and cancer transcripts. Figure 4.4 illustrates 
introduction of a cancer-specific cassette exon by a cancer transcript. 
When we investigated cassette exon distributions within each tissue, 
we found that a striking number of cassette exons are introduced by cancer 
transcripts in most of the tissues. Figure 4.5 shows that in 7 out of the 12 
tissues studied, more than 20% of all cassette exons are introduced by cancer 
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Figure 4.4 Introduction of a cassette exon by a cancer transcript. Cassette 
exon shown by the black arrow appears only in cancer transcripts of the 
variant human cluster Hs.3.chrl2p.4960. Normal transcripts do not have this 
cassette exon. All transcripts of this cluster can be viewed at 
http:/ /genomes.rockefeller.edu/autodb/cluster map.php?cluster id=Hs.3.c 
hrl2p.4960&db=HumanSDB3 (also available at 














J8 cancer only exons 
normal only exons 
Figure 4.5 Introduction of cassette exons by cancer transcripts, y-axis: 
percentage of exons in transcripts of mixed clusters. Red bars denote 
percentage of cassette exons specific to cancer transcripts. Blue bars denote 
percentage of cassette exons specific to normal transcripts. 
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transcripts. These numbers are exceptionally high for thymus at 61.8'V,, for 
skin at 42.1% and for colon at 40.5%. These tissues are followed by 
breast, lung, ovary and kidney, which have 28.1%, 26.7%, 25.9% and 21.8% of 
their cassette exons introduced by cancer transcripts respectively. These 
findings provide quantitative evidence for introduction of cassette exons 
by cancer transcripts, which create variation beyond normal alternative 
splicing and validate presence of aberrant splicing in cancers. 
4.6 Discussion 
Very high numbers of human transcript sequence data heralds from 
cancer cells and cancer tissues. Since aberrant splicing in cancer tissues has 
been widely reported and given our finding that cancer transcripts introduce 
cassette exons beyond normal alternative splicing, it is vital to take into 
account tissue information about transcripts in studies of alternative splicing. 
The vast amount of data from cancer tissues opens up possibilities for 
comparative studies of normal and pathological splicing, following the 
methodology we introduced in this chapter. Future studies of cancer versus 
normal alternative splicing could include investigation of mutually exclusive 
cassette exons, which are present in normal transcripts one at a time. It would 
be of interest to analyze whether these exons are present together in cancer 
transcripts and/or absent from cancer transcripts at the same time. Analysis 
of functional differences in cancer-specific isoforms compared to normal 
isoforms will shed light into many cancer related genes and proteins and will 
open up possibilities for future studies in cancer biology. 
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C H A P T E R 5 
N E U R O N - S P E C I F I C S P L I C I N G R E G U L A T O R N O V A 
5.1 Introduction to N O V A 
Nova-1 is an RNA binding protein specific to neurons. Nova-1 protein 
was isolated as a self-antigen in POMA (paraneoplastic opsoclonus 
myoclonus ataxia), a motor dysfunction autoimmune disorder linked to 
breast cancer (Buckanovich et al, 1996). Expression of Nova-1 is restricted to 
the ventral spinal cord and the hindbrain. Nova-2, another member of the 
Nova protein family, closely associated with Nova-1, is also an RNA binding 
protein and is expressed at regions of brain where Nova-1 is not expressed 
including hippocampus and neocortex (Yang et al, 1998). 
Nova-1 binds to RNA in a sequence specific manner and regulates 
alternative splicing (Jensen et al, 2000a; Dredge et al, 2003). KH domain of 
Nova-1 is necessary for its RNA binding function and recognition of UCAU 
elements on the RNA (Buckanovich and Darnell, 1997; Jensen et al, 2000b). 
Ule et al have developed a novel method called CLIP, which involves 
UV cross-linking and immunoprecipitation, for identification of novel RNA 
targets of Nova. They showed that most of the RNA targets identified code 
for proteins involved in neuronal inhibition and for proteins which function 
at neuronal synapses (Ule et al, 2003). 
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Here w e introduce a novel visualization tool that displays Nova 
binding motifs within target pre-mRNAs for alternative splicing regulation. 
In addition, we describe a computational method for prediction of novel 
target RNAs containing alternative exons potentially regulated by Nova. 
5.2 A Novel Visualization Tool for NOVA Binding Motifs 
We developed a novel tool, which enables visualization of binding 
motifs within sequences of interest. This visualization tool, named TFHunter 
(short for Transcription Factor Hunter since it was originally developed for 
TF binding site searches), is a web-based tool where users can access binding 
site visualizations via a graphical user interface. Partial or full views of pre-
mRNAs with distinct exon and intron structures can be browsed for binding 
motifs. In addition, TFHunter can be made applicable to any target sequences 
and any binding motifs uploaded by users. Web implementation of this tool 
can be accessed at http: / /genomes.rockefeller.edu/yupu-cgi/TFH/ main.cgi 
(Y. Liang private communication). 
5.3 Application of TFHunter to NOVA Binding Sequences 
Using TFHunter we studied the distribution of 7 short sequences 
which are predicted to be major sequences involved in binding of Nova to its 
target sequences (J. Ule, R. Darnell private communication). These motifs 
are illustrated in Figure 5.1. 
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Motif 1: U C A U 
Motif 2: U C A C 
Motif 3: C C A U 
f"o i. 1 Y C A Y C A Y 
Motif 5: Y C A Y Y C A Y 
Motif 6: Y C A Y N Y C A Y 
M o t i f ? : Y C A Y N N Y C A Y 
Figure 5.1 N O V A binding motifs used in TFHunter visualizations. In these 
sequences, Y stands for U or C. N stands for A, U, C or G. 
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W e studied these sequences in a set of genes which contain alternative 
exons regulated by Nova. Microarray experiments have verified that 
expression of each of these exons is either increased or decreased in tissues of 
Nova knockout mice. Table 5.1 provides the list of genes studied and shows 
whether their alternative exon is upregulated or downregulated by Nova. 
Exons which showed an increase in expression are the ones downregulated 
by Nova. Expected binding sites for Nova are either within and/or upstream 
of this group of alternative exons. Exons which showed a decrease in 
expression are the ones upregulated by Nova. Expected binding sites for 
Nova are downstream to this group of alternative exons (J. Ule, R. Darnell 
private communication). 
Figure 5.2 shows neogenin exon 27, an experimentally identified 
alternative exon shown to be downregulated by Nova (Ule et al, 2003). This 
figure illustrates the application of TFHunter to the visualization of Nova 
binding motifs. Colored boxes denote Nova binding motifs described in 
Figure 5.1. Numbers on the right illustrate the number of occurrences of each 
motif within the displayed subsequence of the gene. Numbers in parentheses 
indicate the number of occurrence of each motif within the entire gene. The 
clustered presence of motifs 5 (YCAYYCAY), 6 (YCAYNYCAY) and 7 
(YCAYNNYCAY) denotes potentially strong binding sites for Nova. Similar 
to neogenin, for Chll, Rapl and SkllP genes, TFHunter detected Nova 
binding motifs within the alternative exon and/or upstream to the alternative 
exon. Figures 5.3 and 5.4 show the binding motif clusters in Chll and Rapl 
respectively. 
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Table 5.1 Genes with alternative exons regulated by N O V A 
Gene Alternative Exon Regulation by Nova 
Neogenin 































(Data configured via private communication with J. Ule and R. Darnell). 
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Figure 5.5 shows the TFHunter illustration of Necll gene. As expected, 
Nova-binding motifs cluster downstream of the alternative exon. Similar to 
Necll, for APLP2, Cask, Dbs, Epha5, Fodrin, L AR, PMC A1 and Calsyntenin 
genes, TFHunter detected Nova binding motifs downstream of the 
alternative exons. Figures 5.6, 5.7, 5.8 and 5.9 show clusters of Nova binding 
motifs within APLP2, Epha5, LAR and Calsyntenin respectively. TFHunter 
development is described in Materials and Methods, Section 7.10. All of the 
above findings of Nova binding motif localizations with respect to alternative 
exons are in accordance with our predictions and clusters of long motifs in 
and around cassette exons validate importance of YCAY elements in Nova 
binding to the target RNA molecules (Jensen et al, 2000b). 
5.4 Target Prediction for N O V A 
Here we introduce a computational target prediction method for 
Nova using our alternative splicing databases. Using variant clusters in 
HumanSDB3, MouSDB5 and RatSDB2, we predicted a set of candidate targets 
which contain alternative exons splicing of which is potentially regulated by 
Nova. Our prediction program, called NTHunter (Nova Target Hunter), 
selects a master RNA from each variant cluster. Master RNAs are the 
transcripts with the highest number of exons within a given cluster. From the 
master RNA, NTHunter extracts exon sequences with their 500 base-pair 
upstream and 500 base-pair downstream intronic sequences. 
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Exons are labeled with respect to their variation types. NTHunter 
divides the exon into 100 base-pair regions and searches for Nova binding 
motif clusters within these regions using a sliding window. The window size 
is the number of nucleotides in a given motif and it is indexed at 1 base-pair. 
NTHunter searches for the presence of at least four occurrences of motifs 1, 2 
and/or 3 and at least two occurrences of motifs 4, 5, 6 and/or 7. (Motif 
sequences are shown in Fig. 5.1). If any cassette exon contains a 
combination of these sequences, the transcript containing the given exon is 
flagged as a candidate gene for Nova regulation. Using the above method, we 
predicted 471 human, 136 mouse and 36 rat genes to have one or more 
alternative exons regulated by Nova. Based on the findings discussed in 
Section 5.3, we predict these exons to be downregulated by Nova since these 
genes contain clusters of Nova binding sites within their alternative exons. 
Figure 5.10 provides a partial list of human candidate Nova target genes. The 
complete list of human target genes along with mouse and rat target gene 
lists can be accessed at 
http: / / genomes.rockefeller.edu/ -bahar /NTHunter /NTHunler.html (also 
available at http: / /sgc.ucsd.edu/ -bahar /NTHunter /NTHunter.html). This 
web-page provides, GenBank links of the target genes, their annotations and 
sequences of the potential target cassette exons. Appendices B, C and D show 
the complete lists of human candidate target genes, mouse candidate target 
genes and rat candidate target genes respectively. NTHunter algorithm is 
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Even though known targets for N O V A such as Neogenin, K C N Q and 
Ankyrin (Appendix B) are predicted by NTHunter, when compared to 
constitutive exon background sequence sets randomly selected from 
HumanSDB3, there seems to be no statistical difference between the numbers 
of cassette and constitutive exons predicted by NTHunter. Figure 5.11 shows 
this comparison. Based on this finding and availability of future experimental 
data on alternative splicing regulation by Nova, NTHunter algorithm will be 
modified requiring more stringent clusters of Nova-binding motifs both in 
terms of motif occurrence and in terms of the relative positions of motifs to 
each other within alternative exons and within their flanking intronic 
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Figure 5.11 Eight different background sets of human constitutive exons 
were generated (bl-b8), each of which contained 50,000 exons and had similar 
length distributions of around 136 nucleotides. These background sets were 
compared to a cassette exon set of 50,000 human exons (NTHunter set), of a 
similar length distribution to those of the background exons (around 115 
nucleotides). Number of exons predicted by NTHunter within each of these 
sequence sets are as follows. Cassette exon set (NTHunter set) 
background set-1: 718, background set-2: 748, background set-3 
background set-4: 769, background set-5: 770, background set-6 






We developed a novel visualization method for sequences specific to 
Nova binding to pre-mRNA. With this method, we enable detailed analysis of 
Nova binding sites within target genes. In addition, we computationally 
predicted human, mouse and rat candidate genes with alternative exons 
potentially regulated by Nova. These targets are predicted on the basis of the 
fact that they met a certain threshold for presence of clustered Nova binding 
motifs within their alternative exons. It is of future interest to rank the 
candidate genes by establishing motif density in reference to alternative exon 
position and by taking into account the functional annotation of genes. 
Validation of target genes by experimental methods will lead to 
understanding further the mechanism of regulation of alternative splicing by 
Nova. In addition, our results enable future studies of orthologous Nova 
targets, which will further add to the knowledge on how Nova functions. For 
this purpose, studies of orthologous human-mouse, human-rat, mouse-rat 
gene-pairs and human-mouse-rat gene-triplets for localization of Nova 
binding motifs will be of interest. 
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C H A P T E R 6 
A L T E R N A T I V E S P L I C I N G B E Y O N D M A M M A L I A N 
T R A N S C R I P T O M E S 
6.1 Alternative Splicing a n d M o d e l Organisms 
Alternative splicing has been widely studied in model organisms 
especially in Drosophila melanogaster as discussed in Section 6.2. Since 
alternative splicing is conserved across species (Brett et al, 2002; Valenzuela et 
al, 2004), it is of importance to study this process in species beyond human, 
mouse and rat, in order to understand its evolution and functional 
significance. To this extent, w e developed databases of alternatively spliced 
forms in transcriptomes of Drosophila melanogaster, Caenorhabditis elegans, 
Arabidopsis thaliana and Plasmodium falciparum. These databases are developed 
using the AutoDB pipeline described in Chapters 2 and 7. 
Beyond providing useful information on alternative splicing in these 
organisms, these databases illustrate generality of our approach. AutoDB can 
be applied to genome and transcript sequence data beyond human, mouse 
and rat. 
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6.2 Drosophila melanogaster Alternative Splicing Database 
Drosophila melanogaster is one of the major model organisms used to 
study alternative splicing (Graveley, 2002). Dscam (Down syndrome cell 
adhesion molecule) gene of Drosophila melanogaster contains 95 alternative 
exons and exhibits striking amounts of alternative splicing with more than 
38,000 possible different isoforms. Dscam codes for an axon guidance 
receptor and has been widely studied (Celotto and Graveley, 2001; Graveley 
et al, 2004). 
We developed a database of alternatively spliced transcripts in 
Drosophila melanogaster transcriptome, termed DmelSDB5, using the AutoDB 
pipeline described in Chapter 7. Interactive web implementation of this 
database can be accessed at 
http:/ /sgc.ucsd.edu/autodb/search cIusters.php?db=Dme!SDB5. Tables 6.1 
and 6.2 show numbers of input transcripts, mapped transcripts and transcript 
rejection rates by AutoDB for DmelSDB5. Table 6.3 provides a statistical 
overview of clusters in this database. Table 6.4 shows alternative exon 
distributions in DmelSDB5. 
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Table 6.1 Mapped D. melanogaster transcripts 
Total number of input transcripts 418,023 
Total number of mapped 220,459 
transcripts 
% mapped transcripts 5 3 % 
Average number of transcripts 39.16 
per cluster 
Table 6.2 AutoDB rejection rates for D. melanogaster input transcripts 
Total numbers Percentages 
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£ 
Blat 3365 1.7% 
SIM4 0 0% 
Transcript + Exon Quality 189,545 96% 
Cluster Quality 4,654 2.1 
Total 197,564 
/o 









6 5 % 
Table 6.4 Exons of DmelSDB5 
Exon Numbers 
Total number of exons 47,403 
Constitutive exons 40,257 
Alternative exons 7,146 
Total number of internal cassette exons 1,972 
Length-invariant internal cassette exons 1,725 
5' length-variant internal cassette exons 149 
3' length-variant internal cassette exons 83 
5' and 3' length-variant internal cassette 15 
exons 
Total number of terminal cassette exons 2,225 
Length-invariant terminal cassette exons 1,990 
5' length-variant terminal cassette exons 25 
3' length-variant terminal cassette exons 210 
5' and 3' length-variant terminal cassette 0 
exons 
Total number of length-variant exons 2,949 
5' length-variant exons 1,414 
3' length-variant exons 1,484 
5' and 3' length-variant exons 51 
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6.3 Caenorhabditis elegans Alternative Splicing Database 
C. elegans is one of the major model organisms which displays 
alternative splicing (Zhuang et al, 2003). Using AutoDB, we developed a 
database of alternatively spliced transcripts in C. elegans transcriptome, 
termed CeleganSDB5, which can be accessed at 
http://sgc.ucsd.edu/autodb/search clusters.php?db=CeleganSDB5. Tables 
6.5 and 6.6 show numbers of input transcripts, mapped transcripts and 
transcript rejection rates by AutoDB for CeleganSDB5. Table 6.7 provides a 
statistical overview of clusters in this database. Table 6.8 provides alternative 
exon distributions in CeleganSDB5. 
6.4 Arabidopsis thaliana Alternative Splicing Database 
Available sequence data for Arabidopsis thaliana enables studies of 
alternative splicing in this plant (Iida et al, 2004). Using the AutoDB pipeline 
described in Chapter 7, we developed a database of alternatively spliced 
transcripts in A. thaliana transcriptome, termed AthalSDB3. Interactive web 
implementation of this database can be accessed at 
http: / / sgc.ucsd.edu/ autodb /search clusters.php?db=Atha!SDB3. Tables 6.9 
and 6.10 show numbers of input transcripts, mapped transcripts and 
transcript rejection rates by AutoDB for AthalSDB3. Table 6.11 provides a 
statistical overview of clusters in this database. Table 6.12 shows exon 
distributions in AthalSDB3. 
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Table 6.5 Mapped C. elegans transcripts 
Total number of input transcripts 329,181 
Total number of mapped 122,274 
transcripts 
% mapped transcripts 3 7 % 
Average number of transcripts 24.21 
per cluster 
Table 6.6 AutoDB rejection rates for C. elegans input transcripts 
Total numbers Percentages 
Blat 3,598 1.7% 
SIM4 0 0% 
Transcript + Exon Quality 175,599 8 5 % 
Cluster Quality 27,710 13.3% 
Total 206,907 
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2 3 % 
7 7 % 
Table 6.8 Exons of CeleganSDB5 
Exon Numbers 






Total number of internal cassette exons 1,868 
Length-invariant internal cassette exons 1,762 
5' length-variant internal cassette exons 43 
3' length-variant internal cassette exons 52 
5' and 3' length-variant internal cassette 11 
exons 
Total number of terminal cassette exons 851 
Length-invariant terminal cassette exons 835 
5' length-variant terminal cassette exons 4 
3' length-variant terminal cassette exons 12 
5' and 3' length-variant terminal cassette 0 
exons 
Total number of length-variant exons 2129 
5' length-variant exons 1031 
3' length-variant exons 1052 
5' and 3' length-variant exons 46 
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Table 6.9 Mapped A. thaliana transcripts 
Total number of input transcripts 
Total number of mapped 
transcripts 
% mapped transcripts 




3 1 % 
13.97 


























2 1 % 
79% 
Table 6.12 Exons of AthalSDB3 
Exon Numbers 






Total number of internal cassette exons 1,082 
Length-invariant internal cassette exons 1,026 
5' length-variant internal cassette exons 35 
3' length-variant internal cassette exons 19 
5' and 3' length-variant internal cassette 2 
exons 
Total number of terminal cassette exons 380 
Length-invariant terminal cassette exons 364 
5' length-variant terminal cassette exons 4 
3' length-variant terminal cassette exons 12 
5' and 3' length-variant terminal cassette 0 
exons 
Total number of length-variant exons 3661 
5' length-variant exons 2185 
3' length-variant exons 1411 
5' and 3' length-variant exons 65 
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6.5 P l a s m o d i u m falciparum Alternative Splicing Database 
Given that Plasmodium falciparum is a major pathogen causing malaria, 
and that post-transcriptional regulation including alternative splicing has 
been documented in its transcripts (Singh et al, 2004), we developed a 
database of splice forms in the transcriptome of this organism. 
Database of alternatively spliced transcripts in P falciparum 
transcriptome, termed PfalSDB2, is developed by using the AutoDB pipeline 
described in Chapter 7. Interactive web implementation of this database can 
be accessed at 
http:/ /sgc.ucsd.edu/autodb/search clusters.php?db=Pfa!SDB2. Tables 6.13 
and 6.14 show numbers of input transcripts, mapped transcripts and 
transcript rejection rates by AutoDB for PfalSDB2. Table 6.15 provides a 
statistical overview of clusters in this database. Table 6.16 provides exon 
distributions in PfalSDB2. 
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Table 6.13 Mapped P. falciparum transcripts 
Total number of input transcripts 22,413 
Total number of mapped 2,848 
transcripts 
% mapped transcripts 13% 
Average number of transcripts 11.85 
per cluster 
Table 6.14 AutoDB rejection rates for P. falciparum input transcripts 
Total numbers Percentages 
Blat 579 3 % 
SIM4 0 0 
Transcript + Exon Quality 17,729 9 1 % 
Cluster Quality 1257 6% 
Total 
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Table 6.16 Exons of PfalSDB2 
Exon Numbers 






Total number of internal cassette exons 22 
Length-invariant internal cassette exons 21 
5' length-variant internal cassette exons 0 
3' length-variant internal cassette exons 1 
5' and 3' length-variant internal cassette 0 
exons 
Total number of terminal cassette exons 15 
Length-invariant terminal cassette exons 14 
5' length-variant terminal cassette exons 1 
3' length-variant terminal cassette exons 0 
5' and 3' length-variant terminal cassette 0 
exons 
Total number of length-variant exons 48 
5' length-variant exons 22 
3' length-variant exons 26 
5' and 3' length-variant exons 0 
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6.6 Results 
Figure 6.1a shows overall presence of alternative splicing in Drosophila 
melanogaster, Caenorhabditis elegans, Arabidopsis thaliana and Plasmodium 
falciparum. In Drosophila 35% of clusters are variant, in C. elegans 23% of 
clusters are variant and in Arabidopsis and P. falciparum, 21% and 11% 
clusters are variant respectively. 
Figure 6.1b shows that variation levels detected are positively 
correlated with the average number of transcripts per cluster. This result 
reveals that the extent of alternative splicing detected in genomes of different 
organisms is dependent on the availability of expressed sequence data for 
those organisms. 
When we compare all seven species for which we have developed 
alternative splicing databases, human has the highest prevalence of 
alternative splicing followed by mouse and rat. Drosophila, C. elegans, 
Arabidopsis and P. falciparum display lower levels of variation in descending 
order (Fig. 6.2a). Figure 6.2b shows that there is a positive correlation between 
detection of variation and the number of input transcripts in all seven species. 
However, the fact that rat and Drosophila have similar numbers of input 
transcripts and the finding that there is almost 2-fold higher alternative 
splicing in the rat transcriptome, suggest that more complex organisms might 
have more alternative splicing. A similar argument can be made for 
Drosophila and C. elegans as well (Fig. 6.2b). 
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drosophila c.elegans arabidopsis Plasmodium 
Figure 6.1a Variation in Drosophila, C. elegans, Arabidopsis and P falciparum 
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Figure 6.1b Variation is positively correlated with percent mapped 
transcripts, x-axis: percent variant clusters in each genome, y-axis: average 
number of mapped transcripts per cluster for corresponding genomes. 
128 
Figure 6.2a Alternative splicing across seven different species. Data-points 
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Figure 6.2b Detection of alternative splicing is positively correlated with the 
available expressed sequence data. Data-points show number of input 
transcripts for each organism. 
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6.7 Discussion 
We developed alternative splicing databases for the transcriptomes of 
Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis thaliana and 
Plasmodium falciparum and computed the degree of variation in these 
organisms. These databases show that the method we developed to construct 
alternative splicing databases, namely the AutoDB pipeline, is applicable to 
genomes and transcriptomes beyond human, mouse and rat. 
Our comparative statistical analyses in the seven species for which we 
developed alternative splicing, indicate that alternative splicing is more 
prevalent in genomes of more complex organisms. As further discussed in 
Chapter 8, development of additional databases using genomes of other 
organisms will shed light into how alternative splicing increases the 
complexity of genomes. 
Availability of DmelSDB5, CeleganSDB5, AthalSDB3 and PfalSDB2 
and any future database constructed using AutoDB, will prove useful in 
comparative studies of alternative splicing. Cross-species comparative 
analyses will give insight into functionally important splicing events along 
with species-specific splicing features. 
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C H A P T E R 7 
M A T E R I A L S A N D M E T H O D S 
7.1 D e v e l o p m e n t of Alternative Splicing Databases 
To study alternative splicing we developed three databases for human, 
mouse and rat transcriptomes called HumanSDB3, MouSDB5 and RatSDB2 
respectively as introduced in Chapter 2. These databases are built based on 
modified versions of methods earlier described by Zavolan et al, 2002. All 
three databases were developed using input transcript sequences 
downloaded from UniGene. We used UniGene human version no. 173, 
mouse version no. 139 and rat version no. 134 available from 
ftp: / / ftp.ncbi.nih.gov / repository / UniGene / These transcript sequences 
were aligned to the UCSC genomes hgl7 for human available at 
http://hgdownload.cse.ucsc.edu/goldenPath/hgl7/, mm5 for mouse 
available at http://hgdownload.cse.ucsc.edu/goIdenPath/mm5/, and rn3 
for rat available at 
http: / /hgdownloacl.cse.ucsc.edu/ goldenPath / rnlun2003 / using blat (Kent et 
al, 2002). Top 10% matches from blat reports were aligned to the genomic 
regions by SIM4 (Florea et al, 1998) and the top scoring match was considered 
to be the best alignment. The following criteria were applied to each best-
aligned transcript sequence for inclusion in the final database. The transcript 
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had to have a 7 5 % or greater identity to the genome. In addition, every exon 
of the transcript had to have either a 95% identity to the genome or had to 
contain 5 or less mismatches. Each transcript had to have a minimum of two 
exons. Final clusters had to have a minimum of three transcripts each. Figure 
7.1 shows the AutoDB pipeline used for creating the alternative splicing 
databases. In Chapter 2, Section 2.4 we detail the number of input transcripts 
lost at each step of AutoDB pipeline for HumanSDB3, MouSDB5 and 
RatSDB2. 
DmelSDB5, CeleganSDB5, AthalSDB3 and PfalSDB2 were also 
developed using the AutoDB pipeline. Transcript data sources for full-length 
transcripts and ESTs of Drosophila melanogaster, Caenorhabditis elegans, 
Arabidopsis thaliana and Plasmodium falciparum are GenBank 
(http:/ /www.ncbi.nlm.nih.gov/Genbank/) and dbEST 
(http: / / www.ncbi.nim.nih.gov / dbEST /) respectively. We used Drosophila 
and C. elegans UCSC genome (http:/ /genome.ucsc.edu/) releases dm2 and 
Ce2 respectively. Arabidopsis genome was obtained from GenBank and 
Plasmodium genome was obtained from PlasmoDB (http: / /' plasmodb.org /). 
7.2 Annotation of Alternative a n d Constitutive Exons 
An exon is considered cassette only if one or more transcripts which span 
the given genomic region are missing the given exon. Length variation is 
determined by inspecting all exons of a cluster which fall into the same 
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genomic region. If the 5' end of these exons differ in nucleotide length 
between transcripts, then the exon is flagged as a 5' length-variant exon. 
Likewise, if the 3' end of these exons differ in nucleotide length between 
transcripts, then the exon is flagged as a 3' length-variant exon. In Chapter 1, 
we illustrate cassette and length-variant exons in Figure 1.2. Exons which do 
not differ in nucleotide length and appear in all transcripts sequenced from 
the same gene with the same splice sites are constitutive exons. Alternative 
and constitutive exons are further discussed in Chapter 2, Section 2.2. 
7.3 Definition of Database T e r m s 
For the work described in this thesis, we defined the following terms 
presented in italics. All terms are applicable to all databases. A transcript is a 
sequence transcribed from the genomic DNA sequence. A locus is a genomic 
region that includes a set of overlapping transcripts mapped to the genome 
such that a given transcript appears only in one locus. Within a locus a 
cassette exon is completely included in some transcripts and completely 
excluded from others. A length-variant exon has alternative 5' or 3' splice sites 
or both, in different transcripts. An exon can be both length-variant and 
cassette. A variant exon is either a cassette exon or a length-variant exon or 
both. A genomic exon is an uninterrupted series of nucleotides each of which 
maps to a transcript. A cluster is the set of transcripts that map to a locus. A 
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variant cluster contains one or more variant exons. A n invariant cluster has no 
variant exons (Taneri et al, 2004; Taneri et al, 2005). 
7.4 A u t o D B S c h e m a a n d Statistical Analysis 
AutoDB is built using a relational database system, PostgreSQL-7.4. 
AutoDB schema includes creation of the following six tables: Ouster Table, 
Clone Table, Clone Exon Table, Clone Intron Table, Cds Table and Genomic 
Exon Table. We used Perl DBI interface to perform SQL queries on these 
tables to extract statistical information. Cluster Table contains information on 
types of clusters as variant and invariant. Clone Table contains transcript 
information including tissues from which transcripts are sequenced. Clone 
Exon Table contains information on exons of each transcript in all clusters. 
Clone Intron Table contains information on introns of each transcript in all 
clusters. Genomic Exon Table contains information on all genomic exons from 
each cluster. All of the tables are consisted of several data columns, which are 
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7.5 W e b Implementation of the Databases 
Online access to the PostgreSQL-7.4 splice databases (SDBs) is 
provided at http:/ /genomes.rockefeller.edu/autodb/sdb.php, also mirrored 
at http://genomes.ucsd.edu/autodb/sdb.php. HumanSDB3, MouSDB5 and 
RatSDB2 web pages are dynamically generated by a series of P H P scripts, 
deployed on the Apache-2.0 web server. PostgreSQL database connections 
are carried out via built-in P H P database functions. 
Each AutoDB pipeline-generated SDB has been supplemented by a 
number of additional tables that provide faster online access to the SDB 
statistics and contain information about splice clusters and individual 
chromosomes. 
If a particular splice cluster is accessed the first time through a web 
interface, the P N G graphic cluster maps are generated either by P H P scripts 
or by a PERL script that uses a G D library. The generated graphic files are 
cached for faster subsequent access to the splice cluster. (A. Novoradovsky 
private communication). 
7.6 Computation of Orthologous Splicing Clusters for 
Compare Species Feature 
Computation of orthologous splicing clusters for the Compare Species 
feature of the databases was carried out as follows. Joined genomic exons 
(JGEs) were created for each variant cluster by joining all genomic exons from 
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the genomic exon m a p of each cluster without including any intronic 
sequences. JGEs from one species were aligned to the JGEs of other species 
using tblastx. Pairwise synteny information for human-mouse 
(http:/ /hgdownload.cse.ucsc.edu/goldenPath/hgl7/vsMm5), for human-rat 
(http:/ /hgdownload.cse.ucsc.edu/goldenPath/hgl7/vsRn3) and for mouse-
rat (http:/ /hgdownload.cse.ucsc.edu/golderLPath/mm5/vsRn3) were used 
to establish orthologous clusters. Any JGE pair with an e-value of less than 
1E-04 across more than 10% of the JGE length was considered orthologous. 
All exons from orthologous variant clusters were further aligned using 
tblastx. Exon pairs that matched with an e-value of 1E-04 or lower were 
considered orthologous exons. 
7.7 Analyses of Tissue Distribution of Alternatively Spliced 
Transcripts 
To study tissue-specificity of alternatively spliced isoforms, we defined 
the following four terms associated with each variant cluster. 
(1) homogeneity within tissues: 
all transcripts sequenced from the same tissue have cassette exons with 
same splice sites. 
(2) heterogeneity within tissues: 
transcripts sequenced from the same tissue have cassette exons with 
different splice sites. 
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(3) homogeneity across tissues: 
transcripts sequenced from different tissues have cassette exons with 
same splice sites. 
(4) heterogeneity across tissues: 
transcripts sequenced from different tissues have cassette exons with 
different splice sites. 
To analyze the tissue distribution of alternatively spliced mouse 
transcription factors discussed in Chapter 3, we used 18 tissues chosen from 
the existing libraries in MouSDB3 (a prior release of MouSDB5). These tissues 
were chosen on the basis of the fact that they contain both variant and 
invariant transcripts annotated as TFs. To account for library ambiguities, 
libraries which list several tissues or cell types for a single entry such as 
mixture of brain and testis and libraries which provide no tissue information at 
all such as embryo or carcinoma are screened out. In addition, several parts of a 
given tissue are pooled into one library. For example, the term brain 
corresponds to all parts of the brain found in MouSDB3 libraries, including 
cerebellum, thalamus, hippocampus and 16 other libraries. 
To assess tissue-specificity of mouse TFs within tissues, we used 
homogeneity-to-heterogeneity ratios. To determine the homogeneity-to-
heterogeneity ratio of isoforms within the 18 tissues studied, differences 
between isoforms are established based on the splice sites of cassette exons 
within the coding sequences of transcripts. Variations due to 5' and 3' 
truncations of transcripts are not taken into account. 
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7.8 Analysis of the Effect of Cassette Exons o n Protein D o m a i n 
Architecture 
To analyze the effect of cassette exons on mouse TF domain 
architecture, w e computed in-frame cassette exons which start at codon 
position one within the coding sequences of transcripts and have a nucleotide 
length of a multiple of three. These exons were computationally deleted from 
the TF transcripts. Original and altered coding sequences were translated into 
amino acid sequences and run through S M A R T to determine the altered 
domains. W e illustrate original and altered transcripts along with the S M A R T 
domains computed for their amino acid sequences in Chapter 3, Figure 3.8. 
More information on S M A R T is provided in Chapter 3, Section 3.5. 
7.9 Cancer Tissue Analysis 
Cancer tissue analysis, discussed in Chapter 4, consists of several steps. 
Step one involves extracting all libraries from H u m a n S D B 3 and separating 
those into normal and cancer categories. SQL query for extracting cancer 
libraries was constructed to search for words ending in 'oma', and/or 
beginning with either 'cancer' or 'rumor'. All other library entries were placed 
in the normal tissue list. Both lists were further manually filtered and yielded 
to library lists for 12 tissues as follows: brain, breast, colon, kidney, liver, 
lung, ovary, pancreas, prostate, skin, thymus, and uterus. 
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Using the normal and cancer library lists, w e define variant clusters in 
HumanSDB3 as normal, cancer or mixed. A normal cluster contains transcripts 
sequenced only from normal tissues. A cancer cluster contains transcripts 
sequenced only from cancer tissues. A mixed cluster contains transcripts 
sequenced both from normal tissues and from cancer tissues. Clusters which 
contain transcripts with no library information are not counted. Same cluster 
analysis was repeated within each of the 12 tissues. In addition, statistical 
analysis of exons provided minimum, maximum and average number of 
cassette and length-variant exons for all three types of clusters. 
To assess differences of alternative splicing between normal and cancer 
tissues, we compared cassette exon splice sites from normal and cancer 
transcripts within the same variant clusters previously defined as mixed 
clusters. Transcript numbers sequenced from each tissue and whether or not 
they display different splicing patterns were reported. 
7.10 T F H u n t e r D e v e l o p m e n t 
To find Nova binding sites on uploaded input sequences, TFHunter 
utilizes position weight matrices for each binding motif not allowing for any 
mismatches. A postscript scores the input sequence using sliding windows 
based on position weight matrices. Each window size is equal to a given 
motif size. (Nova binding motif sequences are provided in Chapter 5, Fig. 
5.1). Images of binding motif localizations on input sequences are web 
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implemented using GD.pm scripts and can be accessed at 
http: / /genomes.rockefeller.edu/yupu-cgi/TFH/main.cgi. 
7.11 N T H u n t e r Algorithm 
As introduced in Chapter 5, our prediction program, called NTHunter 
(Nova Target Hunter), selects a master RNA from each variant cluster. Master 
RNAs are the transcripts with the highest number of exons within a given 
cluster. From the master RNA, NTHunter extracts exon sequences with their 
500 base-pair upstream and 500 base-pair downstream intronic sequences. 
Exons are labeled with respect to their variation types. NTHunter divides the 
exon into 100 base-pair regions and searches for Nova binding motif clusters 
within these regions using a sliding window. Window size is the size of a 
given motif and it is indexed at 1 base-pair. NTHunter searches for presence 
of at least 4 of motifs 1, 2 and /or 3 and at least 2 of motifs 4, 5, 6 and/or 7. 
(Motif sequences are shown in Chapter 5, Fig. 5.1). If any cassette exon is 
picked up by NTHunter, the transcript containing the given exon is flagged 
as a candidate gene for Nova regulation. 
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7.12 Sampling D e p t h Controls 
Sampling depth denotes the absolute number of transcripts of a given 
gene sequenced from a given tissue. Since some tissues are more frequently 
used in DNA libraries, in all our analyses we account for sampling depths 
from each tissue. To control for any sampling depth bias, the absolute 
number of transcripts sequenced per tissue is normalized in each analysis. 
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C H A P T E R 8 
C O N C L U S I O N S 
8.1 Discussion of Results 
The work described in this thesis provides quantitative evidence for 
contribution of tissue-specific alternative splicing to the complexity of 
transcriptomes and proteomes. In this study, along with three new databases 
of alternative splicing in human, mouse, rat transcriptomes and 
computational methods to compare variant transcription at gene loci, we 
introduce a novel web-based visualization method to study comparative 
alternative splicing. This tool brings to the end-user the ability to analyze 
alternative splicing in their gene of interest. Users can view all exons of their 
gene, access their nucleotide sequences and learn about the libraries of the 
transcripts sequenced for that gene. In addition, users are able to find 
orthologous human-mouse, human-rat and mouse-rat pairs for their genes of 
interest and to study pairs of orthologous constitutive and alternative exons 
in detail. 
Our analyses of the human, mouse and rat transcriptomes show that 
alternative splicing is widespread within all three species. Overall variation in 
human loci is 81%. Variant mouse and rat loci are 74% and 58% respectively. 
In all three transcriptomes, alternative splicing is mainly due to the presence 
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or absence of cassette exons. 6 7 % of human alternative exons are cassette 
exons, as are 62% of mouse and 62% of rat alternative exons. This finding 
indicates functional significance of this type of alternative exons. 
In addition, our results show widespread presence of a specific subset 
of cassette exons which are present either at the 5' or at the 3' ends of 
transcripts. These exons, termed transcript-terminal cassette exons, do not 
map to any other genomic exon within their cluster, but rather map to 
intronic sequences. Transcript-terminal exons are either due to alternative 
starts and ends of transcription or they might be due to sequence artifacts. 
Through integrated analyses of DNA and protein sequences for 
transcription factor (TF) genes, we show that alternative splicing of TFs is 
more prevalent in the entire mouse transcriptome and in specific tissues 
when compared to alternatively spliced forms of all variant genes. In 78% of 
the analyzed tissues, a higher proportion of TFs exhibit alternative splicing 
than does the set of all variant genes in the mouse transcriptome. This result 
along with the finding that 62% of mouse TF loci are variant indicates the 
widespread impact of alternative splicing on regulation of transcription factor 
function. 
We show that alternative splicing changes TF structure by adding or 
deleting domains via cassette exons. Our study reveals that 80% of 
alternatively spliced mouse TFs have different domain architectures due to 
introduction of an in-frame cassette exon by alternative splicing. 75% of the 
altered domains play a role in DNA binding. These findings provide 
quantitative evidence for the role of alternative splicing in controlling the 
presence of domains in proteins. They also suggest that alternative splicing 
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might regulate TF activity and thus alter gene expression by changing the 
DNA-binding domain architecture of these proteins. 
Our analyses reveal that within a single tissue there generally is only 
one TF isoform, and across tissues, TF isoforms differ. This finding indicates 
tissue specificity of alternatively spliced TFs and suggests that TFs might 
regulate gene expression in a tissue specific manner by having different 
isoforms in different tissues. In addition, our study shows that all variant loci 
in the mouse transcriptome display isoform homogeneity within single 
tissues and heterogeneity across different tissues, indicating tissue-specificity 
of alternatively spliced mouse genes. This finding greatly expands the 
knowledge on contribution of alternative splicing to tissue-specific expression 
of mouse genes. 
In addition, we show that in the human transcriptome, there is a high 
prevalence of transcript sequence data from cancer tissues. More than 80% of 
human variant loci contain transcripts from cancer tissues. Further, we show 
that cancer transcripts introduce variation beyond normal alternative 
splicing. In the majority of tissues, more than 20% of the cassette exons are 
from cancer transcripts only. Our results quantitatively validate presence of 
aberrant alternative splicing in cancer sequence data. 
Lastly, by studying alternatively spliced genes in transcriptomes of 
Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis thaliana and 
Plasmodium falciparum in comparison to those in human, mouse and rat, we 
showed that alternative splicing is more prevalent in genomes of more 
complex organisms. 
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8.2 Implications of W o r k a n d Future Directions 
The work described in this thesis has implications in several different 
fields and paves way to numerous future studies as described below. 
(a) Alternative Splicing and Complexity of Genomes 
The databases described in this thesis provide detailed information on 
alternative splicing in three mammalian transcriptomes, Homo sapiens, Mus 
musculus and Rattus norvegicus, as well as alternative splicing in three model 
organisms, Drosophila melanogaster, Caenorhabditis elegans, Arabidopsis thaliana 
and a pathogen Plasmodium falciparum. Our studies on these organisms 
indicate that there is more alternative splicing in more complex organisms 
and that there is an elevation of alternative splicing in mammalian genomes. 
To further investigate whether alternative splicing increases as organisms get 
more complex, it is of future interest to run AutoDB on available expressed 
sequence data and genomes of several other organisms including the 
following. 
Fugu rubripes (Fugu) 
Danio rerio (Zebrafish) 
Caenorhabditis briggsae (Worm) 
Gallus gallus (Chicken) 
Pan troglodytes (Chimpanzee) 
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Ciona intestinalis (Sea squirt) 
Oryza sativa (Rice) 
Statistical analysis of alternative splicing in transcriptomes of the 
organisms listed above, along with the statistical analysis provided in this 
thesis will shed light on how alternative splicing increases the complexity of 
different genomes. 
(b) Comparative Analysis of Conserved Alternative Splicing 
The work described here has significant implications in further 
understanding the evolution, function and regulation of alternative splicing. 
We provide a novel method for studying conservation of alternative splicing. 
Our visualization tool for orthologous exon pairs provides a means for 
comparative studies of alternative exons in human-mouse, human-rat and 
mouse-rat gene-pairs. Easy access to comparative alternative splicing data 
together with instant information retrieval about the variant exons and their 
sequences further aids in experimental design for alternative splicing studies. 
The Compare Species tool we developed opens up possibilities for 
studies of not only the conserved sequences, but also the non-conserved 
species-specific features such as exons that are present only in human and not 
in mouse. This feature can also be used in identification of shadozv exons. Such 
149 
exons are annotated in one species, they are present in the intronic sequence 
of the other species but they have not yet been annotated as exons. 
In addition, future work using the Compare Species tool could focus 
on investigating parallelism in splicing patterns across species, particularly 
on human, mouse, rat gene-pairs and gene-triplets. Concordance of genomic 
structures of homologous genes with respect to alternative exons and their 
variation types could provide insight into functionally important splicing 
events. In addition, parallelism in characteristics of alternative exons could be 
studied, such as reading frame preservation. 
It is of further interest to extend comparative studies of alternatively 
spliced genes beyond mammalian genomes. For this purpose, the three 
databases described in this thesis for transcriptomes of Drosophila 
melanogaster, Caenorhabditis elegans and Arabidopsis thaliana will prove useful. 
In addition new splicing databases in organisms mentioned in Section 8.2a of 
this chapter could provide resources for detailed analysis of conserved 
alternative exons. 
Species analysis could be extended to more closely related organisms 
such as human, chimpanzee and macaque and compared to more distantly 
related organisms such as mouse. Identification of splicing events present in 
human, chimpanzee and macaque but not in mouse can reveal evolutionarily 
important alternative splicing events and show how alternative splicing 
increases genome complexity of higher organisms. 
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(c) Aberrant Alternative Splicing in Cancer Transcripts 
Our studies point to high prevalence of cancer transcripts in the 
human transcriptome data which lead to introduction of variation beyond 
normal alternative splicing. These findings imply that future studies of 
alternative splicing should take into account differences of variation between 
normal and cancer transcripts. Future analysis of cancer-specific cassette 
exons should focus on transcripts from tumor tissues only. Exclusion of 
transcripts from cancer cell lines would provide more accurate information 
with regards to the cassette exons introduced by cancer transcripts. Normal-
only cassette exons would be determined in the same way by comparative 
studies of transcripts from normal tissues and tumor tissues. In addition to 
studies of cancer-specific cassette exons described in this thesis, it would be of 
further interest to investigate differences of length-variant exons between 
transcripts sequenced from normal and cancer tissues. 
(d) N O V A Regulated Alternative Splicing 
Our studies on neuron specific splicing regulator NOVA point to the 
importance of studying tissue-specific RNA binding proteins and indicate 
that motif searches in tissue-specific sets of transcripts would lead to 
identification of novel regulators of splicing specific to given tissues. 
To expand the studies on NOVA binding motifs described in this 
thesis, the program GoMiner (Zeeberg et al, 2003) could be used to get 
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functional annotations of predicted N O V A target genes. Genes that function 
at the synapses and in axon guidance would be of higher priority to be 
experimentally tested. In addition, identification of orthologous human-
mouse, human-rat and mouse-rat target gene-pairs and human-mouse-rat 
target gene-triplets would prove useful for NOVA binding site searches. 
Genes which have orthologous targets and function either as a synaptic 
protein or in axon guidance would be tested experimentally. RT-PCR could 
be used as a method to validate regulation of these candidate alternative 
exons by NOVA. 
Furthermore, to learn more about regulation of alternative exons by 
NOVA, orthologous sets of human, mouse and rat alternative exons can be 
generated, based on experimentally identified mouse exons, which are 
known to be either upregulated or downregulated by NOVA. A set of 
alternative exons which are not regulated by NOVA would be used as a 
control sequence set. In these sets of sequences, searches for NOVA binding 
motifs can be developed on variations of YCAY motifs. In addition, 
overrepresentation of any other motifs could be investigated. Any newly 
identified motifs could function as binding sites for other RNA-binding 
proteins which might act antagonistically to NOVA. 
NOVA was identified as a self-antigen in an autoimmune motor 
dysfunction disorder called POMA (Buckanovich et al, 1996). This disorder 
occurs in patients with certain cancers, such as breast and ovarian cancer, 
when neuron-specific proteins are expressed in tumor cells. In this thesis, we 
have shown existence of cancer-specific alternative exons. It would be of 
special interest to study this notion with respect to NOVA. To this extent, 
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cassette exons in nervous tissues such as brain and cassette exons in 
cancerous breast and ovarian tissues would be compared to the cassette exons 
in normal ovary and breast tissues. This approach would lead to 
identification of neuron-specific cassette exons expressed in cancer tissues. 
Understanding tissue-specificity of alternative splicing is key to 
understanding how this biological process contributes to differential gene 
expression. Therefore, in addition to studies of tissue-specific RNA binding 
proteins, it is of particular interest to study global tissue-specificity of distinct 
isoforms of alternatively spliced genes. To address this question global 
comparative tissue-distribution analysis in orthologous sets of alternatively 
spliced genes in human-mouse, human-rat and mouse-rat can be performed. 
Furthermore, investigation of temporal specificity of distinct isoforms would 
provide insight into the role of alternative splicing during development and 
differentiation. 
(e) Global Detection of Alternative Splicing Events via Splicing Arrays 
A natural extension of the studies described in this thesis would be the 
development of robust measurements for tissue-specific splice forms. For this 
purpose, microarrays which measure tissue-specific splicing events and 
methods to detect tissue-specific alternative splicing from microarray 
expression data are being developed. To this extent, Yeakley et al. describe a 
fibre-optic array used to analyze alternative splicing in human genes (Yeakley 
et al, 2002). Pan et al. utilize a quantitative microarray to study tissue-specific 
alternative splicing in mouse genes (Pan et al, 2004). Wang et al. describe a 
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splice array and introduce an algorithm which detects known splice variants 
(Wang et al, 2003). Le et al develop a method for detection of tissue-specific 
alternative splicing from microarray data (Le et al, 2004). Yeo et al. study 
distribution of alternative splicing across human tissues utilizing microarray 
expression data (Yeo et al, 2004). Johnson et al. utilize exon junction 
microarrays to study alternative splice forms of human genes on a whole 
genome scale Qohnson et al, 2003). 
Information in our databases will enable production of splicing 
microarrays which measure the expression levels of alternatively spliced 
isoforms of genes. These microarrays can be on a whole genome scale and 
they can be built for different species such as human and mouse. The work 
described here implies contribution of alternative splicing to regulation of 
gene expression via tissue specific TF isoforms and thus indicates that future 
high-throughput screens of gene expression analyses should be sensitive to 
multiple alternatively spliced forms of TFs. Since gene expression arrays are 
intended to measure transcription, the next generation of arrays should 
contain probes specific to all known isoforms of genes represented on the 
arrays. 
Splicing chip data together with the information in our alternative 
splicing databases will enable individual experiments such as validation of 
tissue-specific isoforms by quantitative PCR, which can verify the existence of 
different isoforms and will lead to functional characterization of isoforms via 
further experiments. All this effort will lead to a better understanding of 







splicing chips experiments 
Figure 8.1 Overview of expansion of alternative splicing research. 
Information provided in HumanSDB3, MouSDB5, RatSDB2, DmelSDB5, 
CeleganSDB5, AthalSDB3 and PfalSDB2 will lead to possible splicing 
microarrays and further wet-lab experiments. 
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(f) Effect of Alternative Splicing on Protein Structures 
Given the fact that alternatively spliced exons are highly conserved 
across species (Sorek and Ast, 2003), it would be of further interest to study 
the effect of cassette exons on proteomes of other organisms. Strong sequence 
homology between mouse, human and rat exons suggests that a comparative 
analysis of human, mouse and rat TF variations will be a natural extension of 
the studies described here. 
Other sets of proteins which are widely alternatively spliced are 
kinases and G-protein coupled receptors. The studies on the effect of cassette 
exons on protein domain architecture could be expanded to these sets of 
proteins. It would be of special interest to investigate if alternative splicing 
regulates these proteins by targeting a specific functional domain of these 
proteins, as we have shown in this thesis for transcription factor DNA 
binding domains. 
In addition, it would be of further interest to investigate differential 
effects of major an minor forms of cassette exons in protein domain 
architectures. Major forms of cassette exons appear in more than 50% of the 
sequenced transcripts and minor forms of cassette exons appear in less than 
50% of the sequenced transcripts of a given gene (Modrek and Lee, 2003). 
Analysis of effects of species-specific minor cassette exons on protein domain 
architecture would be of special interest. 
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(g) Transcript-initial and Transcript-terminal Cassette Exons 
Our results point out to high occurrences of transcript-initial and 
transcript-terminal cassette exons. To gain more information on transcript-
initial (5'-most exon) and transcript-terminal (3'-most exon) cassette exons, we 
will study the properties of these exons including nucleotide length 
distribution of these exons, their frame preservation, tissue distribution and 
whether or not they are conserved across human, mouse and rat. In addition, 
average number of constitutive and average number of alternative exons in 
transcripts containing transcript-initial and transcript-terminal cassette exons 
could be compared to those numbers in transcripts which do not have these 
exons. Upstream regions of transcript-initial cassette exons could be analyzed 
for gene expression regulatory sequences and transcript-terminal cassette 
exons could be analyzed for presence of polyadenylation signals. These 
analyses will help determine whether transcript-initial and transcript-
terminal cassette exons are real starts and ends of transcription or they are 
due to errors in splicing and /or sequencing. Furthermore, future studies of 
alternative splicing should take into account the transcript-initial and 
transcript-terminal cassette exons when investigating variation within 
transcriptomes. 
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(h) Regulation of Length-Variation in Alternative Exons 
Our studies point to an intron-centric regulation of length variation in 
alternative exons rather than an exon-centric regulation. To further 
investigate this process, conserved intronic sequence elements flanking the 
human, mouse and rat length-variant exons could be studied. Searches for 
splicing regulatory sequence elements within the length-variant exons and 
comparing these to the conserved sequence elements in their flanking intronic 
regions will provide insight into regulation of length-variation in alternative 
exons. 
(i) Investigating Potential Regulation of Alternative Splicing by 
m i R N A s 
miRNAs are small non-coding RNA molecules which play an 
important role in translational repression of m R N A s (Pasquinelli and 
Ruvkun, 2002). Previous studies indicate possible regulation of alternative 
splicing by m i R N A s in Arabidopsis thaliana (X. Wang, Dissertation 2004). To 
investigate the notion of regulation of alternative splicing via m i R N A s in 
human and mouse, H u m a n S D B 3 and MouSDB5 databases described in this 
thesis can be utilized. m i R N A s could silence splicing by binding to splice 
sites. To investigate the degree to which this happens in alternatively spliced 
human and mouse genes, exon-intron junctions and exon-exon junctions of 
alternative exons could be searched for potential m i R N A binding sequences. 
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A P P E N D I X A 
LIST OF PROTEIN DOMAINS ALTERED BY CASSETTE 
EXONS (FROM CHAPTER 3) 
Cluster ID Transcription Factor Annotation Domains Altered by 
Cassette Exons 
Sell 8190 Calcium-independent Phosholipase 
A 2 Isoform 2 
Scll8706 Dream/calsenilin 
Scll9415 transcription factor PBX3a (PBX3) 
Scll9959 hepatocyte nuclear factor 4 
Scl22286 Evi-1 transcription factor splice 
variant delta 105 
Scl22515 weakly similar to multifunctional 
aminotransferase (KAT) / (GTK) 
Scl23794 similar to nuclear matrix 
transcription factor 
Scl24819 transcription elongation factor TFIIS 
Scl25542 nuclear transcription factor, X-box 
binding 1 
Scl27217 TFIIH basal transcription factor 
complex P34 subunit 
Scl29156 CCR4-NOT transcription complex, 
subunit 4 
Scl29710 microphthalmia-associated 
transcription factor (Mitf) 












rrm, coiled coil 
HLH 
















SRY-box containing gene 6 (Sox6) 
upstream transcription factor 2 
(Usf2) 
N K 6 transcription factor related 
Transcription factor IIB 
transcriptional regulator, SIN3A 
TTF-I interacting protein 5 (TIP5 
gene) 
transcription factor UBF 
myocardin A (BSAC2A), 
alternatively spliced 
transcription factor 7, T-cell specific 
flotillin 2 (Flot2) 
Kruppel-like factor 12 (Klfl2) 
activator protein 4 (Ap4) 
similar to zinc finger transcription 
factor TREP-132 
c A M P responsive element binding 
protein-like 1 
H M G B O X 
H L H 
exo-endo-phos 
Kinase, DUF667 
P A H 
M B D , AT_hook, D D T , 
bromodomain, P H D 
H M G 
SAP 
H M G B O X 
band-7, flotillin 
znf-c2h2 
H L H , coil 
znf-c2h2, ELM2, myb-
D N A binding 
BRLZ, BZIP, coil 
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A P P E N D I X B 
LIST OF HUMAN TARGET GENES PREDICTED BY NTHunter 
( F R O M C H A P T E R 5) 
GenBank ID 

























m R N A for PRP8 protein, complete cds 
m R N A for KIAA0697 protein, partial cds 
m R N A for p51B, complete cds 
cBGLl m R N A for cytosolic beta-glucosidase-like protein-1, 
complete cds 
DLEC1 (deleted in lung and esophageal cancer 1; DLEC1 
alias DLC1) m R N A , complete cds 
m R N A for KIAA0987 protein, partial cds 
m R N A for KIAA0987 protein, partial cds 
m R N A for KIAA1250 protein, partial cds 
hLAT2 m R N A for L-type amino acid transporter 2, 
complete cds 
ALS2CR8 m R N A , complete cds, long form 
hShrmL m R N A for Shroom-related protein, complete cds 
RBBP6 m R N A for retinoblastoma binding protein 6 isoform 
1, complete cds 
casein kinase I g a m m a 2 primary transcript, complete cds 
killer cell receptor (KIR103) m R N A , allele LP, complete cds 
proline-rich Gla protein 1 (PRGP1) m R N A , complete cds 
beta-dystrobrevin (BDTN) m R N A , complete cds 
branched chain alpha-ketoacid dehydrogenase kinase 
precursor, m R N A , nuclear gene encoding mitochondrial 
protein, complete cds 
natural killer cell inhibitory receptor (KIR2DL4) m R N A , 
variant 1, complete cds 
natural killer cell inhibitory receptor (KIR2DL4) m R N A , 
variant 3, complete cds 
Eph-like receptor tyrosine kinase hEphBlc (EphBl) m R N A , 
complete cds 
unknown protein IT12 m R N A , partial cds 
PRUNE-like protein m R N A , complete cds 

































dysferlin m R N A , complete cds 
splicing factor Prp8 m R N A , complete cds 
dachshund ( D A C H ) m R N A , complete cds 
P2X2B receptor m R N A , complete cds 
cell cycle checkpoint protein (R24L) m R N A , complete cds 
A B C protein m R N A , complete cds 
DDP-like protein m R N A , complete cds 
ubiquitin-specific processing protease (USP25) m R N A , 
complete cds 
glycoprotein-associated amino acid transporter LAT2 
(LAT2) m R N A , complete cds 
polycystic kidney disease-like 2 protein (PKDL2) m R N A , 
complete cds 
P2X2B receptor (P2X2) m R N A , complete cds 
BM-015 m R N A , complete cds 
GL008 m R N A , complete cds 
RALBP1 m R N A , complete cds 
purinoceptor P2X2B (P2X2) m R N A , complete cds, 
alternatively spliced 
clone KIR2DL4v4 killer-cell Ig-like receptor m R N A , 
complete cds 
regulator of nonsense transcripts 2 (RENT2) m R N A , 
complete cds 
testis development protein P R T D [Homo sapiens], m R N A 
sequence 
testis development protein P R T D [Homo sapiens], m R N A 
sequence 
cytosolic beta-glucosidase m R N A , complete cds 
UPF2 (UPF2) m R N A , complete cds 
OSBP-related protein 6 m R N A , complete cds 
cytosolic beta-glucosidase (CBG) m R N A , complete cds 
N A D P H oxidase 5 beta m R N A , complete cds 
N A D P H oxidase 5 beta m R N A , complete cds 
Four-span transmembrane protein 1 (4SPAN1) m R N A , 
complete cds 
dachshund (DACH) m R N A , complete cds 
S O N D N A binding protein isoform C (SON) m R N A , 
complete cds, alternatively spliced 
S O N D N A binding protein isoform E (SON) m R N A , 
complete cds, alternatively spliced 
oxysterol-binding protein-like protein OSBPL6 (OSBPL6) 































CD109 [Homo sapiens], m R N A sequence 
tensin 3 m R N A , complete cds 
KCCR13L m R N A , complete cds 
BCL8B protein (BCL8B) m R N A , complete cds 
chemokine-like factor super family 3 (CKLFSF3) m R N A , 
complete cds 
chemokine-like factor super family 3 (CKLFSF3) m R N A , 
complete cds 
BRCC1 (BRCC1) m R N A , complete cds 
E3 ubiquitin ligase (TRIAD3A) m R N A , complete cds; 
alternatively spliced 
E3 ubiquitin ligase (TRIAD3B) m R N A , complete cds; 
alternatively spliced 
unknown m R N A 
prestin (PRES) m R N A , complete cds 
m R N A for SAP 130 spliceosomal protein 
m R N A for dachshund protein 
m R N A for ZASP protein, partial, varient 3 
m R N A for transmembrane glycoprotein (CD44 gene) 
m R N A for kainate receptor subunit (GRIK2 gene) 
partial m R N A for cytosolic beta-glucosidase (GLUC gene) 
m R N A for M U C 4 protein splice variant svl3 ( M U C 4 gene) 
m R N A for M U C 4 protein splice variant svl3 ( M U C 4 gene) 
m R N A for steerin2 protein (STEERIN2 gene) 
C M P D 0 1 H o m o sapiens c D N A clone CMPD08387, m R N A 
sequence 
c D N A FLJ10138 fis, clone HEMBA1003148, highly similar 
to H o m o sapiens m R N A full length insert c D N A clone 
E U R O I M A G E 381801 
cDNA: FLJ23274 fis, clone HEP02623, highly similar to 
AF161354 H o m o sapiens HSPC091 Mrna 
cDNA: FLJ23462 fis, clone HSI08475 
cDNA: FLJ23602 fis, clone LNG15735 
c D N A FLJ14469 fis, clone M A M M A 1 0 0 0 8 9 7 , weakly similar 
to INTER-ALPHA-TRYPSIN INHIBITOR H E A V Y C H A I N 
H 3 P R E C U R S O R 
c D N A FLJ31164 fis, clone KIDNE1000104, weakly similar to 
S Y N T A X I N 7 
c D N A FLJ31190 fis, clone KIDNE2000403 
c D N A FLJ31654 fis, clone NT2RI2004230, highly similar to 






















c D N A FLJ31762 fis, clone NT2RI2007754, weakly similar to 
INTESTINAL M E M B R A N E A 4 PROTEIN 
c D N A FLJ31762 fis, clone NT2RI2007754, weakly similar to 
INTESTINAL M E M B R A N E A 4 PROTEIN 
c D N A FLJ31850 fis, clone NT2RP7000600, highly similar to 
H o m o sapiens activating receptor PILRbeta m R N A 
c D N A FLJ32257 fis, clone PROST1000262, highly similar to 
V A S O A C T I V E INTESTINAL POLYPEPTIDE R E C E P T O R 1 
P R E C U R S O R 
c D N A FLJ32313 fis, clone PROST2003232, weakly similar to 
B E T A - G L U C U R O N I D A S E P R E C U R S O R (EC 3.2.1.31) 
c D N A FLJ23790 fis, clone HEP21466 
c D N A FLJ90051 fis, clone HEMBA1002551, weakly similar 
to PUTATIVE SERINE 
c D N A FLJ90263 fis, clone NT2RM4000997, weakly similar 
to M O N O - A N D D I A C Y L G L Y C E R O L LIPASE 
P R E C U R S O R (EC 3.1.1.-) 
c D N A FLJ90291 fis, clone NT2RP1001031, weakly similar to 
VEGETATIBLE INCOMPATIBILITY PROTEIN HET-E-1 
c D N A FLJ90600 fis, clone PLACE1001401, weakly similar to 
H I G H AFFINITY I M M U N O G L O B U L I N EPSILON 
R E C E P T O R BETA-SUBUNIT 
c D N A FLJ90647 fis, clone PLACE1004282, weakly similar to 
M O N O - A N D D I A C Y L G L Y C E R O L LIPASE P R E C U R S O R 
(EC 3.1.1.-) 
c D N A PSEC0071 fis, clone NT2RP2002115, weakly similar 
to INTER-ALPHA-TRYPSIN INHIBITOR H E A V Y C H A I N 
H 3 P R E C U R S O R (ITI H E A V Y C H A I N H3) (SERUM-
DERIVED H Y A L U R O N A N - A S S O C I A T E D PROTEIN) 
(SHAP) 
c D N A PSEC0104 fis, clone NT2RP2004795 
c D N A PSEC0260 fis, clone NT2RP3004059 
m R N A for FLJ00348 protein 
c D N A FLJ34203 fis, clone FCBBF3019784, highly similar to 
Mouse m R N A for seizure-related gene product 6 type 2 
precursor 
c D N A FLJ34671 fis, clone LIVER2001099, moderately 
similar to Rattus norvegicus m R N A for putative integral 
membrane transport protein 
c D N A FLJ35039 fis, clone OCBBF2017035, highly similar to 
M u s musculus m R N A for G A T S protein 
c D N A FLJ35438 fis, clone SMINT2002884, weakly similar to 
C M R F 3 5 A N T I G E N P R E C U R S O R 
c D N A FLJ35984 fis, clone TESTI2014097, highly similar to 























c D N A FLJ36308 fis, clone THYMU2004916, highly similar 
to B R A N C H E D - C H A I N A M I N O ACID 
A M I N O T R A N S F E R A S E , M I T O C H O N D R I A L 
P R E C U R S O R (EC 2.6.1.42) 
c D N A FLJ38070 fis, clone CTONG2015518 
c D N A FLJ39197 fis, clone OCBBF2005077, moderately 
similar to CARNITINE O-PALMITOYLTRANSFERASE I, 
M I T O C H O N D R I A L LIVER I S O F O R M (EC 2.3.1.21) 
c D N A FLJ39583 fis, clone SKMUS2004897, highly similar to 
ACTIN, A L P H A SKELETAL M U S C L E 
c D N A FLJ25787 fis, clone TST06855, highly similar to 
C Y C L I N - D E P E N D E N T KINASE INHIBITOR 3 (EC 
3.1.3.48) 
c D N A FLJ25800 fis, clone TST07092 
c D N A FLJ16118 fis, clone ASTRO2013585 
c D N A FLJ16272 fis, clone NT2NE2018916, weakly similar to 
POLYPEPTIDE N-
A C E T Y L G A L A C T O S A M I N Y L T R A N S F E R A S E ( E C 
2.4.1.41) 
c D N A FLJ41911 fis, clone PEBLM2008605, highly similar to 
V E R Y - L O N G - C H A I N A C Y L - C O A S Y N T H E T A S E (EC 
6.2.1.-) 
c D N A FLJ42146 fis, clone TESTI4000434, highly similar to 
H o m o sapiens SPG protein (SPG) m R N A 
c D N A FLJ42279 fis, clone TLIVE2002690 
c D N A FLJ43387 fis, clone OCBBF2006764, highly similar to 
M u s musculus seizure related gene 6 (Sez6) 
c D N A FLJ43447 fis, clone OCBBF2032590, weakly similar to 
H.sapiens m R N A for melanoma-associated chondroitin 
sulfate proteoglycan 
c D N A FLJ43860 fis, clone TESTI4007404 
c D N A FLJ44038 fis, clone TESTI4028880, highly similar to 
Glucose transporter type 3, brain 
c D N A FLJ44038 fis, clone TESTI4028880, highly similar to 
Glucose transporter type 3, brain 
c D N A FLJ44038 fis, clone TESTI4028880, highly similar to 
Glucose transporter type 3, brain 
c D N A FLJ44606 fis, clone BRACE2005991 
c D N A FLJ44813 fis, clone BRACE3044495, weakly similar to 
H o m o sapiens GROS1-L protein 
c D N A FLJ45086 fis, clone BRAWH3028796, highly similar 
to H o m o sapiens makorin, ring finger protein, 1 (MKRN1) 
c D N A FLJ45956 fis, clone PLACE7011072, highly similar to 




























c D N A FLJ45956 fis, clone PLACE7011072, highly similar to 
Vacuolar A T P synthase subunit B, kidney isoform (EC 
3.6.1.34) 
c D N A FLJ46562 fis, clone THYMU3040172, highly similar 
to T-cell differentiation antigen C D 6 precursor 
c D N A FLJ16059 fis, clone TESTI2029252, weakly similar to 
H o m o sapiens m R N A for LAK-4p 
c D N A FLJ16586 fis, clone TESTI4000137 
m R N A full length insert c D N A clone E U R O I M A G E 381801 
m R N A full length insert c D N A clone E U R O I M A G E 609395 
m R N A ; c D N A DKFZp564E227 (from clone 
DKFZp564E227); complete cds 
N E U R O B L A S T O M A C O T 25-NORMALIZED H o m o 
sapiens c D N A clone CS0DC005YA21 5-PRIME, m R N A 
sequence 
N E U R O B L A S T O M A C O T 25-NORMALIZED H o m o 
sapiens c D N A clone CS0DC021YL21 5-PRIME, m R N A 
sequence 
c D N A DKFZp313I2410 (from clone DKFZp31312410) 
c D N A DKFZp586G2119 (from clone DKFZp586G2119) 
c D N A DKFZp434D0316 (from clone DKFZp434D0316) 
N R E B P m R N A , complete cds 
S L A M m R N A , complete cds 
M T O l protein isoform III m R N A , complete cds; nuclear 
gene for mitochondrial product 
M T O l protein isoform IV m R N A , complete cds; nuclear 
gene for mitochondrial product 
M L L 5 (MLL5) m R N A , complete cds; alternatively spliced 
activated T-cell marker CD109 (CD109) m R N A , complete 
cds 
dolichyl pyrophosphate phosphatase C W H 8 m R N A , 
complete cds 
inter-alpha trypsin inhibitor heavy chain precursor 5 
(ITIH5) m R N A , complete cds 
prestin isoform SLC26A5b (PRES) m R N A , complete cds 
truncated transient receptor potential cation channel 
subfamily M member 6 variant a (TRPM6) m R N A , 
complete cds, alternatively spliced 
G protein coupled receptor 133 (GPR133) m R N A , complete 
cds 
growth hormone-releasing hormone receptor m R N A , 
complete cds 
200 kDa U 5 snRNP-specific spliceosomal protein (BRR2) 
























constitutive androstane receptor SV1 (NR1I3) m R N A , 
partial cds, alternatively spliced 
constitutive androstane receptor SV2 (NR1I3) m R N A , 
complete cds, alternatively spliced 
constitutive androstane receptor SV14 (NR1I3) m R N A , 
partial cds, alternatively spliced 
natural killer cell immunoglobulin-like receptor (KIR2DL4) 
m R N A , complete cds 
zinc finger protein 76 (expressed in testis), m R N A (cDNA 
clone M G C 5 0 5 9 IMAGE:2900036), complete cds 
translocase of inner mitochondrial membrane 8 homolog B 
(yeast), m R N A (cDNA clone M G Q 1 1 0 2 IMAGE:2823930), 
complete cds 
LIM homeobox 3, m R N A (cDNA clone IMAGE:3354063), 
containing frame-shift errors 
zinc finger protein 76 (expressed in testis), m R N A (cDNA 
clone M G Q 1 5 7 7 IMAGE:3139040), complete cds 
mitochondrial translation optimization 1 homolog (S. 
cerevisiae), m R N A (cDNA clone IMAGE:3842973), partial 
cds 
ATP-dependent glucokinase, m R N A (cDNA clone 
M G Q 1 2 9 7 5 IMAGE:3347312), complete cds 
branched chain alpha-ketoacid dehydrogenase kinase, 
m R N A (cDNA clone M G C 1 6 1 3 8 IMAGE:3630050), 
complete cds 
dolichyl pyrophosphate phosphatase 1, m R N A (cDNA 
clone IMAGE:3938659), partial cds 
FAST kinase, transcript variant 1, m R N A (cDNA clone 
M G C 1 9 7 8 4 IMAGE:3831196), complete cds 
RALBP1 associated Eps domain containing 1, m R N A 
(cDNA clone M G G 1 6 2 2 8 IMAGE:3677286), complete cds 
hypothetical protein MGC4189, m R N A (cDNA clone 
IMAGE:4149678) 
hypothetical protein MGC4189, m R N A (cDNA clone 
IMAGE:4149678) 
hypothetical protein PP1665, m R N A (cDNA clone 
M G G 3 2 0 4 6 IMAGE:4845520), complete cds 
dachshund homolog 1 (Drosophila), m R N A (cDNA clone 
IMAGE:4301720), partial cds 
c D N A clone IMAGE:4819705, containing frame-shift errors 
TcD37 homolog, m R N A (cDNA clone MGG39274 
IMAGE:5458046), complete cds 
T U W D 1 2 , m R N A (cDNA clone M G C 2 6 7 5 3 
IMAGE:4827689), complete cds 
KCCR13L, m R N A (cDNA clone M G G 2 6 7 6 5 
























dolichyl pyrophosphate phosphatase 1, m R N A (cDNA 
clone M G Q 4 5 3 8 9 IMAGE:5195127), complete cds 
chloride channel Ka, m R N A (cDNA clone IMAGE:5172279), 
containing frame-shift errors 
chromosome 9 open reading frame 68, m R N A (cDNA clone 
IMAGE:5168196), complete cds 
FLJ44216 protein, m R N A (cDNA clone MGG33586 
IMAGE:4823991), complete cds 
tumor protein p73-like, m R N A (cDNA clone M G G 4 8 6 7 8 
IMAGE:5552611), complete cds 
alpha-2-macroglobulin, m R N A (cDNA clone MGC:47683 
IMAGE:6056126), complete cds 
erythrocyte membrane protein band 4.1-like 1, m R N A 
(cDNA clone M G G 3 4 7 6 4 IMAGE:5195986), complete cds 
killer cell immunoglobulin-like receptor, two domains, long 
cytoplasmic tail, 4, m R N A (cDNA clone MGC:52132 
IMAGE:5485491), complete cds 
Similar to G protein-coupled hepta-helical receptor Ig-
Hepta, clone IMAGE:5295143, m R N A 
ATP-dependent glucokinase, m R N A (cDNA clone 
I M A G E 5269974), partial cds 
Similar to RIKEN c D N A 6720460106 gene, clone 
IMAGE:4428383, m R N A 
clone IMAGE:5311299, m R N A 
similar to bK246H3.1 (immunoglobulin lambda-like 
polypeptide 1, pre-B-cell specific), m R N A (cDNA clone 
IMAGE:5728597), partial cds 
hypothetical protein MGC4189, m R N A (cDNA clone 
M G G 6 0 1 7 2 IMAGE:5493799), complete cds 
hypothetical protein MGC4189, m R N A (cDNA clone 
M G G 6 0 1 7 2 IMAGE:5493799), complete cds 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 8, transcript variant 1, m R N A (cDNA 
clone M G G 5 9 7 9 4 IMAGE:6260264), complete cds 
C-terminal binding protein 1, m R N A (cDNA clone 
M G C 5 9 8 3 1 IMAGE:6461670), complete cds 
hypothetical protein FLJ10211, m R N A (cDNA clone 
IMAGE:6501489), partial cds 
dihydropyrimidinase-like 2, m R N A (cDNA clone 
M G G 6 4 8 7 3 IMAGE:6044141), complete cds 
hypothetical protein LOC163782, m R N A (cDNA clone 
M G G 7 1 8 1 4 IMAGE:30344114), complete cds 
chromosome 7 open reading frame 2, m R N A (cDNA clone 
IMAGE:4803998), partial cds 
TRIAD3 protein, transcript variant 2, m R N A (cDNA clone 
























PRP8 pre-mRNA processing factor 8 homolog (yeast), 
m R N A (cDNA clone M G G 7 4 7 6 2 IMAGE:5587081), 
complete cds 
cytochrome b reductase 1, m R N A (cDNA clone M G G 7 4 7 1 6 
IMAGE:6063145), complete cds 
cut-like 1, C C A A T displacement protein (Drosophila), 
m R N A (cDNA clone MGC:75164 IMAGE:5740343), 
complete cds 
dihydropyrimidinase-like 2, m R N A (cDNA clone 
M G G 7 0 8 4 6 IMAGE:3870039), complete cds 
splicing factor 3b, subunit 3,130kDa, m R N A (cDNA clone 
M G G 7 4 9 4 3 IMAGE:6168677), complete cds 
nuclear receptor subfamily 1, group I, member 3, m R N A 
(cDNA clone M G G 9 7 2 0 9 IMAGE:7262456), complete cds 
c D N A clone IMAGE:30346915, containing frame-shift 
errors 
balOalO.yl N I H _ M G C _ 7 H o m o sapiens c D N A clone 
IMAGE:2823930 5' similar to S W : D D P _ H U M A N 060220 X-
LINKED D E A F N E S S D Y S T O N I A PROTEIN. [1];, m R N A 
sequence 
601107535F1 NIH_MGC_16 H o m o sapiens c D N A clone 
IMAGE:3343856 5', m R N A sequence 
601107535F1 NIH_MGC_16 H o m o sapiens c D N A clone 
IMAGE:3343856 5', m R N A sequence 
601116738F1 NIH_MGC_16 H o m o sapiens c D N A clone 
IMAGE:3357440 5', m R N A sequence 
601109728F1 NIH_MGC_16 H o m o sapiens c D N A clone 
IMAGE:3350455 5', m R N A sequence 
601275187F1 NIH_MGC_20 H o m o sapiens c D N A clone 
IMAGE:3616317 5', m R N A sequence 
601306301F1 NIH_MGC_39 H o m o sapiens c D N A clone 
IMAGE:3640585 5', m R N A sequence 
601592447F1 N I H _ M G C _ 7 H o m o sapiens c D N A clone 
IMAGE:3946571 5', m R N A sequence 
601587161F1 N I H _ M G C _ 7 H o m o sapiens c D N A clone 
IMAGE:3941463 5', m R N A sequence 
601435329F1 N I H _ M G C _ 7 2 H o m o sapiens c D N A clone 
IMAGE:3920358 5', m R N A sequence 
601496630F1 NIH_MGC_70 H o m o sapiens c D N A clone 
IMAGE:3898878 5', m R N A sequence 
602255757F1 NIH_MGC_85 H o m o sapiens c D N A clone 
IMAGE:4339094 5', m R N A sequence 
602309628F1 NIH_MGC_88 H o m o sapiens c D N A clone 
IMAGE:4400694 5', m R N A sequence 
602491929F1 N I H _ M G C _ 2 0 H o m o sapiens c D N A clone 
IMAGE:4623078 5', m R N A sequence 
602541857F1 NIH_MGC_59 H o m o sapiens c D N A clone 


























602658151F1 NCI_CGAP_Skn3 H o m o sapiens c D N A clone 
IMAGE:4800780 5', m R N A sequence 
602688932F1 NIH_MGC_95 H o m o sapiens c D N A clone 
IMAGE:4821366 5', m R N A sequence 
602668979F1 NIH_MGC_96 H o m o sapiens c D N A clone 
IMAGE:4791762 5', m R N A sequence 
602668992F1 NIH_MGC_96 H o m o sapiens c D N A clone 
IMAGE:4791622 5', m R N A sequence 
602693661F1 N E H _ M G C _ 9 7 H o m o sapiens c D N A clone 
IMAGE:4825839 5', m R N A sequence 
602747021F2 N I H _ M G C _ 1 7 H o m o sapiens c D N A clone 
IMAGE:4899941 5', m R N A sequence 
603254010F1 N I H _ M G C _ 9 7 H o m o sapiens c D N A clone 
IMAGE:5296442 5', m R N A sequence 
603022935F1 NIH_MGC_114 H o m o sapiens c D N A clone 
IMAGE:5193584 5', m R N A sequence 
603025836F1 NIH_MGC_114 H o m o sapiens c D N A clone 
IMAGE:5196321 5', m R N A sequence 
603055864F1 NIH_MGC_122 H o m o sapiens c D N A clone 
IMAGE:5205374 5', m R N A sequence 
AGENCOURT_6390834 N I H _ M G C _ 6 7 H o m o sapiens 
c D N A clone IMAGE:5493799 5', m R N A sequence 
AGENCOURT_6390834 NIH_MGC_67 H o m o sapiens 
c D N A clone IMAGE:5493799 5', m R N A sequence 
AGENCOURT_6497810 NIH_MGC_125 H o m o sapiens 
c D N A clone IMAGE:5588307 5', m R N A sequence 
AGENCOURT_6497810 NIH_MGC_125 H o m o sapiens 
c D N A clone IMAGE:5588307 5', m R N A sequence 
UI-E-EJl-ajj-l-01-0-UI.sl UI-E-EJ1 H o m o sapiens c D N A 
clone UI-E-EJl-ajj-l-01-0-UI 3', m R N A sequence 
K-EST0021829 S3SNU16sl H o m o sapiens c D N A clone 
S3SNU16sl-2-EH 5', m R N A sequence 
K-EST0116904 S13KMS5 H o m o sapiens c D N A clone 
S13KMS5-31-G08 5', m R N A sequence 
AGENCOURT_6763708 NIH_MGC_68 H o m o sapiens 
c D N A clone IMAGE:5792711 5', m R N A sequence 
AGENCOURT_7554671 NIH_MGC_72 H o m o sapiens 
c D N A clone IMAGE:6063145 5', m R N A sequence 
AGENCOURT_7805574 NIH_MGC_92 H o m o sapiens 
c D N A clone IMAGE:6068214 5', m R N A sequence 
AGENCOURT_8109235 Lupski_sympathetic_trunk H o m o 
sapiens c D N A clone IMAGE:6189375 5', m R N A sequence 
AGENCOURT_8794262 NIH_MGC_18 H o m o sapiens 
c D N A clone IMAGE:6370682 5', m R N A sequence 
AGENCOURT_8794262 NIH_MGC_18 H o m o sapiens 
c D N A clone IMAGE:6370682 5', m R N A sequence 
AGENCOURT_7968610 NIH_MGC_68 H o m o sapiens 
c D N A clone IMAGE:6011181 5', m R N A sequence 
170 
BUI76606.2 AGENCOURT_7825223 N I H _ M G C _ 6 7 H o m o sapiens 
c D N A clone IMAGE:6142965 5', m R N A sequence 
BU500170.2 AGENCOURT_7859851 N I H _ M G C _ 6 4 H o m o sapiens 
c D N A clone IMAGE:6108978 5', m R N A sequence 
BU528662.3 AGENCOURT_10183145 NIH_MGC_101 H o m o sapiens 
c D N A clone IMAGE:6538626 5', m R N A sequence 
BU541379.2 AGENCOURT_l0333359 N I H _ M G C _ 4 0 H o m o sapiens 
c D N A clone IMAGE:6573052 5', m R N A sequence 
BU655927.5 cl04bl2.zl Hembase; Erythroid Precursor Cells (LCBxl 
library) H o m o sapiens c D N A clone cl04bl2 5', m R N A 
sequence 
BU656904.3 cll7f06.zl Hembase; Erythroid Precursor Cells (LCBxl 
library) H o m o sapiens c D N A clone cll7f06 5', m R N A 
sequence 
BU659919.5 cl53f03.zl Hembase; Erythroid Precursor Cells (LCBxl 
library) H o m o sapiens c D N A clone cl53f03 5', m R N A 
sequence 
BU853397.5 AGENCOURT_10417826 NIH_MGC_82 H o m o sapiens 
c D N A clone IMAGE:6620233 5', m R N A sequence 
BX095212.5 BX095212 Soares fetal liver spleen 1NFLS H o m o sapiens 
c D N A clone IMAGp998A19654, m R N A sequence 
BX100703.4 BX100703 Soares_parathyroid_tumor_NbHPA H o m o 
sapiens c D N A clone IMAGp998D21684, m R N A sequence 
BX330997.4 BX330997 H o m o sapiens H E L A CELLS C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone 
CS0DK005YM04 3-PRIME, m R N A sequence 
BX330997.5 BX330997 H o m o sapiens H E L A CELLS C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone 
CS0DK005YM04 3-PRIME, m R N A sequence 
BX335807.3 BX335807 H o m o sapiens P L A C E N T A C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone CS0DI020YE24 
5-PRIME, m R N A sequence 
BX335807.4 BX335807 H o m o sapiens P L A C E N T A C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone CS0DI020YE24 
5-PRIME, m R N A sequence 
BX353062.2 BX353062 H o m o sapiens N E U R O B L A S T O M A C O T 10-
N O R M A L I Z E D H o m o sapiens c D N A clone CS0DB008YL06 
5-PRIME, m R N A sequence 
BX362900.4 BX362900 H o m o sapiens H E L A CELLS C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone 
CS0DK005YM04 5-PRIME, m R N A sequence 
BX362900.5 BX362900 H o m o sapiens H E L A CELLS C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone 
CS0DK005YM04 5-PRIME, m R N A sequence 
BX367559.5 BX367559 H o m o sapiens N E U R O B L A S T O M A C O T 10-
N O R M A L I Z E D H o m o sapiens c D N A clone 

























BX374377 H o m o sapiens N E U R O B L A S T O M A C O T 10-
N O R M A L I Z E D H o m o sapiens c D N A clone 
CS0DB001YH22 5-PRIME, m R N A sequence 
BX398157 H o m o sapiens P L A C E N T A C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone CS0DI053YH10 
5-PRIME, m R N A sequence 
BX398157 H o m o sapiens P L A C E N T A C O T 25-
N O R M A L I Z E D H o m o sapiens c D N A clone CS0DI053YH10 
5-PRIME, m R N A sequence 
BX441333 H o m o sapiens FETAL BRAIN H o m o sapiens 
c D N A clone CS0DF016YN22 5-PRIME, m R N A sequence 
BX460119 H o m o sapiens FETAL BRAIN H o m o sapiens 
c D N A clone CS0DF011YC02 5-PRIME, m R N A sequence 
m R N A ; c D N A DKFZp779G2251 (from clone 
DKFZp779G2251); complete cds 
m R N A ; c D N A DKFZp686B0852 (from clone 
DKFZp686B0852); complete cds 
m R N A ; c D N A DKFZp686I155 (from clone DKFZp686I155) 
m R N A ; c D N A DKFZp686I155 (from clone DKFZp686I155) 
m R N A ; c D N A DKFZp686I155 (from clone DKFZp686I155) 
m R N A ; c D N A DKFZp77902152 (from clone 
DKFZp77902152); complete cds 
m R N A ; c D N A DKFZp686E1588 (from clone 
DKFZp686E1588); complete cds 
m R N A ; c D N A DKFZp686E1588 (from clone 
DKFZp686E1588); complete cds 
m R N A ; c D N A DKFZp686E18109 (from clone 
DKFZp686E18109); complete cds 
m R N A ; c D N A DKFZp686E18109 (from clone 
DKFZp686E18109); complete cds 
m R N A ; c D N A DKFZp686K15188 (from clone 
DKFZp686K15188) 
m R N A ; c D N A DKFZp686B14144 (from clone 
DKFZp686B14144) 
m R N A ; c D N A DKFZp779N0852 (from clone 
DKFZp779N0852) 
m R N A ; c D N A DKFZp779A1459 (from clone 
DKFZp779A1459) 
m R N A ; c D N A DKFZp686E07118 (from clone 
DKFZp686E07118) 
m R N A ; c D N A DKFZp313O0321 (from clone 
DKFZp313O0321) 
m R N A ; c D N A DKFZp686P0286 (from clone 
DKFZp686P0286) 


























m R N A ; c D N A DKFZp686E0628 (from clone 
DKFZp686E0628) 
m R N A ; c D N A DKFZp686G13268 (from clone 
DKFZp686G13268) 
m R N A ; c D N A DKFZp779D1050 (from clone 
DKFZp779D1050) 
m R N A ; c D N A DKFZp686F0129 (from clone 
DKFZp686F0129) 
AGENCOURT_10738534 M A P c L H o m o sapiens c D N A 
clone IMAGE:6718791 5', m R N A sequence 
AGENCOURT_10735752 M A P c L H o m o sapiens c D N A 
clone IMAGE:6722619 5', m R N A sequence 
K-EST0184328 L12JSHC0sl H o m o sapiens c D N A clone 
L12JSHC0sl-l-F05 5', m R N A sequence 
90115366 Single gene library H o m o sapiens cDNA, m R N A 
sequence 
90115482 Single gene library H o m o sapiens cDNA, m R N A 
sequence 
90115350 Single gene library H o m o sapiens cDNA, m R N A 
sequence 
56072143H1 FLPRSV H o m o sapiens cDNA, m R N A 
sequence 
EST10890 human nasopharynx H o m o sapiens cDNA, 
m R N A sequence 
UI-HF-ES0-avz-p-15-0-UI.rl NIH_MGC_213 H o m o sapiens 
c D N A clone IMAGE:30561686 5', m R N A sequence 
17000600176961 G R N _ P R E N E U H o m o sapiens c D N A 5', 
m R N A sequence 
17000600176961 G R N _ P R E N E U H o m o sapiens c D N A 5', 
m R N A sequence 
17000423762706 G R N _ E B H o m o sapiens c D N A 5', m R N A 
sequence 
17000424180130 G R N _ E S H o m o sapiens c D N A 5', m R N A 
sequence 
17000455125353 G R N _ E B H o m o sapiens c D N A 5', m R N A 
sequence 
hw07b05.yl H u m a n primary human ocular pericytes. 
Unamplified (hw) H o m o sapiens c D N A clone hw07b05 5', 
m R N A sequence 
hw27c07.yl H u m a n primary human ocular pericytes. 
Unamplified (hw) H o m o sapiens c D N A clone hw27c07 5', 
m R N A sequence 
full-length c D N A clone CS0DI065YO02 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DB003YG07 of Neuroblastoma 
Cot 10-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DK003YB10 of HeLa cells Cot 


























full-length c D N A clone CS0DA004YC14 of Neuroblastoma 
of H o m o sapiens (human) 
full-length c D N A clone CS0DB002YB21 of Neuroblastoma 
Cot 10-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI020YE24 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI020YE24 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI008YN22 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DK010YC14 of HeLa cells Cot 
25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DA009YH03 of Neuroblastoma 
of H o m o sapiens (human) 
full-length c D N A clone CS0DI029YM17 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DC015YO12 of Neuroblastoma 
Cot 25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DK005YM04 of HeLa cells Cot 
25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DK005YM04 of HeLa cells Cot 
25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DF004YA19 of Fetal brain of 
H o m o sapiens (human) 
full-length c D N A clone CS0DJ014YK18 of T cells (Jurkat cell 
line) Cot 10-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI034YK18 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DK007YF19 of HeLa cells Cot 
25-normalized of H o m o sapiens (human 
full-length c D N A clone CS0DC002YM14 of Neuroblastoma 
Cot 25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI085YK18 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DL009YD13 of B cells (Ramos 
cell line) Cot 25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI042YI18 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI041YC02 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DL005YO09 of B cells (Ramos 
cell line) Cot 25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DL001YG03 of B cells (Ramos 
cell line) Cot 25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DK002YM17 of HeLa cells Cot 
25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DN001YM15 of Adult brain of 





























full-length c D N A clone CS0DB001YH22 of Neuroblastoma 
Cot 10-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DM003YB16 of Fetal liver of 
H o m o sapiens (human) 
full-length c D N A clone CS0DK002YO07 of HeLa cells Cot 
25-normalized of H o m o sapiens (human) 
full-length c D N A clone CS0DI015YK13 of Placenta Cot 25-
normalized of H o m o sapiens (human) 
KIAA0046 m R N A , partial cds 
m R N A for dihydropyrimidinase related protein-2, 
complete cds. 
m R N A for HCS, complete cds. 
m R N A for KIAA0017 protein, partial cds 
m R N A for very-long-chain acyl-CoA synthetase, complete 
cds. 
m R N A for mitochondrial acetoacetyl-CoA thiolase 
precursor, complete cds 
H u m a n growth hormone-releasing hormone receptor 
m R N A , complete cds. 
H u m a n multidrug resistance-associated protein (MRP) 
m R N A , complete cds 
growth hormone releasing hormone receptor, human, G-
protein coupled receptor, secretin family 
H u m a n activin receptor-like kinase (ALK-5) m R N A , 
complete cds. 
protein tyrosine phosphatase (CIP2)mRNA, complete cds. 
H u m a n protein phosphatase (KAP1) m R N A , complete cds. 
H u m a n alpha-2-macroglobulin m R N A , complete cds. 
H o m o sapiens dystrophin ( D M D ) m R N A , complete cds. 
H u m a n displacement protein (CCAAT) m R N A . 
H o m o sapiens rac protein kinase-beta m R N A , complete 
cds. 
H u m a n interleukin 5 receptor alpha-subunit (IL5R) m R N A 
alpha-2-macroglobulin (A2M), m R N A 
acetyl-Coenzyme A acetyltransferase 1 (acetoacetyl 
Coenzyme A thiolase) (ACAT1), nuclear gene encoding 
mitochondrial protein, m R N A 
ATPase, Cu++ transporting, beta polypeptide (Wilson 
disease) (ATP7B), m R N A 
damage-specific D N A binding protein 2, 48kDa (DDB2), 
m R N A 
dystrophin (muscular dystrophy, Duchenne and Becker 
types) (DMD), transcript variant Dp427c, m R N A 
interleukin 5 receptor, alpha (IL5RA), transcript variant 1, 






















CD44 antigen (homing function and Indian blood group 
system) (CD44), transcript variant 1, m R N A 
growth hormone releasing hormone receptor (GHRHR), 
m R N A 
guanylate cyclase 1, soluble, alpha 3 (GUCY1A3), m R N A 
guanylate cyclase 1, soluble, alpha 3 (GUCY1A3), m R N A 
proline rich Gla (G-carboxyglutamic acid) 1 (PRRG1), 
m R N A 
ankyrin 2, neuronal (ANK2), transcript variant 1, m R N A 
chloride channel 6 (CLCN6), transcript variant ClC-6a, 
m R N A 
dihydropyrimidinase-like 2 (DPYSL2), m R N A 
v-akt murine thymoma viral oncogene homolog 2 (AKT2), 
m R N A 
killer cell immunoglobulin-like receptor, two domains, long 
cytoplasmic tail, 4 (KIR2DL4), m R N A 
macrophage scavenger receptor 1 (MSR1), transcript 
variant SR-AII, m R N A 
signaling lymphocytic activation molecule family member 1 
(SLAMF1), m R N A 
S O N D N A binding protein (SON), transcript variant g, 
m R N A 
zinc finger protein 76 (expressed in testis) (ZNF76), m R N A 
dysferlin, limb girdle muscular dystrophy 2B (autosomal 
recessive) (DYSF), m R N A 
tumor protein p73-like (TP73L), m R N A 
dystrophin (muscular dystrophy, Duchenne and Becker 
types) (DMD), transcript variant Dp427m, m R N A 
dystrophin (muscular dystrophy, Duchenne and Becker 
types) (DMD), transcript variant Dp427pl, m R N A 
dystrophin (muscular dystrophy, Duchenne and Becker 
types) (DMD), transcript variant Dp427p2, m R N A 






N M 005106.11 
ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 
(ATP2A1), transcript variant b, m R N A 
chondroitin sulfate proteoglycan 2 (versican) (CSPG2), 
m R N A 
transforming growth factor, beta receptor I (activin A 
receptor type II-like kinase, 53kDa) (TGFBR1), m R N A 
potassium voltage-gated channel, Shaw-related subfamily, 
member 3 (KCNC3), m R N A 
ATP-binding cassette, sub-family C (CFTR 
deleted in lung and esophageal cancer 1 (DLEC1), 






























N M 024345.5 
nuclear receptor subfamily 1, group I, member 3 (NR1I3), 
m R N A 
cyclin-dependent kinase inhibitor 3 (CDK2-associated dual 
specificity phosphatase) (CDKN3), m R N A 
epidermal growth factor receptor (erythroblastic leukemia 
viral (v-erb-b) oncogene homolog, avian) (EGFR), transcript 
variant 1, m R N A 
branched chain alpha-ketoacid dehydrogenase kinase 
(BCKDK), m R N A 
PRP8 pre-mRNA processing factor 8 homolog (yeast) 
(PRPF8), m R N A 
FAST kinase (FASTK), transcript variant 1, m R N A 
retinoblastoma binding protein 6 (RBBP6), transcript 
variant 1, m R N A 
solute carrier family 7 (canonic amino acid transporter, y+ 
system), member 8 (SLC7A8), transcript variant 1, m R N A 
erythrocyte membrane protein band 4.1-like 3 (EPB41L3), 
m R N A 
erythrocyte membrane protein band 4.1-like 3 (EPB41L3), 
m R N A 
splicing factor 3b, subunit 3,130kDa (SF3B3), m R N A 
apoptotic protease activating factor (APAF1), transcript 
variant 1, m R N A 
paired immunoglobin-like type 2 receptor beta (PILRB), 
transcript variant 1, m R N A 
U 5 snRNP-specific protein, 200-KD (U5-200KD), m R N A 
senataxin (KIAA0625), m R N A 
senataxin (KIAA0625), m R N A 
UPF2 regulator of nonsense transcripts homolog (yeast) 
(UPF2), transcript variant 2, m R N A 
neurobeachin (NBEA), m R N A 
g20 protein (LOC51161), m R N A 
hypothetical protein FLJ10521 (FLJ10521), m R N A 
dolichyl pyrophosphate phosphatase 1 (DOLPP1), m R N A 
Shroom-related protein (ShrmL), m R N A 
glucosidase, beta, acid 3 (cytosolic) (GBA3), m R N A 
ankyrin 3, node of Ranvier (ankyrin G) (ANK3), transcript 
variant 1, m R N A 
TcD37 homolog (HTCD37), m R N A 
dystrobrevin, beta (DTNB), transcript variant 1, m R N A 
tensin (TNS), m R N A 
hypothetical protein MGC5297 (MGC5297), m R N A 
hypothetical protein MGC10765 (MGC10765), m R N A 
177 
NM_024505.10 N A D P H oxidase, EF hand calcium-binding domain 5 
(NOX5), m R N A 
NM_024611.15 N M D A receptor-regulated gene 2 (NARG2), m R N A 
NM_024744.5 amyotrophic lateral sclerosis 2 (juvenile) chromosome 
region, candidate 8 (ALS2CR8), m R N A 
NM_024843.2 cytochrome b reductase 1 (CYBRD1), m R N A 
NM_030569.13 inter-alpha (globulin) inhibitor H 5 (ITIH5), transcript 
variant 1, m R N A 
NM_031284.2 ATP-dependent glucokinase (ADP-GK), m R N A 
NM_031846.7 microtubule-associated protein 2 (MAP2), transcript variant 
3, m R N A 
NM_031922.14 H o m o sapiens RALBP1 associated Eps domain containing 1 
(REPS1), m R N A 
NM_032217.26 ankyrin repeat domain 17 (ANKRD17), transcript variant 1, 
m R N A 
NM_032523.19 oxysterol binding protein-like 6 (OSBPL6), transcript 
variant 1, m R N A 
NMJD58183.3 S O N D N A binding protein (SON), transcript variant e, 
m R N A 
NM_080599.11 UPF2 regulator of nonsense transcripts homolog (yeast) 
(UPF2), transcript variant 1, m R N A 
NM_080759.5 dachshund homolog 1 (Drosophila) (DACH1), transcript 
variant 1, m R N A 
NM_130854.12 protein tyrosine phosphatase, receptor type, S (PTPRS), 
transcript variant 2, m R N A 
NM_133338.5 R A D 1 7 homolog (S. pombe) (RAD17), transcript variant 1, 
m R N A 
NM_133493.21 CD109 antigen (Gov platelet alloantigens) (CD109), m R N A 
NM_133645.4 mitochondrial translation optimization 1 homolog (S. 
cerevisiae) (MTOl), m R N A 
NM_138576.3 B-cell CLL 
NM_138925.4 S O N D N A binding protein (SON), transcript variant a, 
m R N A 
NM_138926.3 S O N D N A binding protein (SON), transcript variant c, 
m R N A 
NM_139179.4 KCCR13L (LOC221955), m R N A 
NM_144601.3 chemokine-like factor super family 3 (CKLFSF3), transcript 
variant 1, m R N A 
NM_144601.4 chemokine-like factor super family 3 (CKLFSF3), transcript 
variant 1, m R N A 
NM_144963.6 hypothetical protein FLJ23790 (FLJ23790), m R N A 
NM_145003.4 hypothetical protein FLJ31164 (FLJ31164), m R N A 





























N M 212475.28 
crystallin, zeta (quinone reductase)-like 1 (CRYZL1), 
transcript variant 3, m R N A 
E2a-Pbxl-associated protein (EB-1), transcript variant 1, 
m R N A 
hypothetical protein MGC35048 (MGC35048), m R N A 
Meisl, myeloid ecotropic viral integration site 1 homolog 2 
(mouse) (MEIS2), transcript variant b, m R N A 
Meisl, myeloid ecotropic viral integration site 1 homolog 2 
(mouse) (MEIS2), transcript variant a, m R N A 
T U W D 1 2 (TUWD12), m R N A 
purinergic receptor P2X, ligand-gated ion channel, 2 
(P2RX2), transcript variant 2, m R N A 
casein kinase 2, alpha 1 polypeptide (CSNK2A1), transcript 
variant 1, m R N A 
chemokine-like factor super family 1 (CKLFSF1), transcript 
variant 8, m R N A 
chemokine-like factor super family 1 (CKLFSF1), transcript 
variant 9, m R N A 
chemokine-like factor super family 1 (CKLFSF1), transcript 
variant 20, m R N A 
chemokine-like factor super family 1 (CKLFSF1), transcript 
variant 21, m R N A 
cut-like 1, C C A A T displacement protein (Drosophila) 
(CUTL1), transcript variant 1, m R N A 
chemokine-like factor super family 3 (CKLFSF3), transcript 
variant 3, m R N A 
chemokine-like factor super family 3 (CKLFSF3), transcript 
variant 3, m R N A 
hypothetical protein LOC163782 (LOC163782), m R N A 
apoptotic protease activating factor (APAF1), transcript 
variant 3, m R N A 
myeloid 
Neuron navigator 2 (NAV2), transcript variant 1, m R N A 
FLJ44216 protein (FLJ44216), m R N A 
G protein-coupled receptor 133; G-protein coupled receptor 
GPR133 [Homo sapiens], m R N A sequence 
prestin (motor protein) (PRES), transcript variant a, m R N A 
prestin (motor protein) (PRES), transcript variant b, m R N A 
TRIAD3 protein (TRIAD3), transcript variant 1, m R N A 
TRIAD3 protein (TRIAD3), transcript variant 2, m R N A 
FLJ43860 protein (FLJ43860), m R N A 
fibronectin 1 (FN1), transcript variant 2, m R N A 






























X M 371561.5 
fibronectin 1 (FN1), transcript variant 2, m R N A 
H o m o sapiens hemochromatosis type 2 (juvenile) (HFE2), 
transcript variant a, m R N A 
cyclin-dependent kinase interactor 1; Cdil [Homo sapiens], 
m R N A sequence 
H u m a n P-type ATPase ATP7B m R N A , complete cds 
H u m a n hydroxyindole-O-methyltransferase promoter A-
derived (HIOMT) m R N A , complete cds. 
H u m a n copper transporting ATPase m R N A , complete cds. 
ankyrin G (ANK-3) m R N A , complete cds. 
H u m a n chondroitin sulfate proteoglycan versican VO 
splice-variant precursor peptide m R N A , complete cds. 
H u m a n collapsin response mediator protein hCRMP-2 
m R N A , complete cds. 
damage-specific D N A binding protein p48 subunit (DDB2) 
m R N A , complete cds. 
alpha (1,3 
signaling lymphocytic activation molecule (SLAM) m R N A , 
complete cds. 
H u m a n protein tyrosine phosphatase PTPsigma 
(PTPsigma) m R N A , complete cds. 
H u m a n natural killer cell receptor (KIR) m R N A , complete 
cds 
H u m a n meningioma-expressed antigen 6 (MEA6) m R N A , 
complete cds 
H u m a n m R N A for precursor of epidermal growth factor 
receptor 
soluble guanylate cyclase large subunit m R N A 
soluble guanylate cyclase large subunit m R N A 
m R N A for putative chloride channe 
m R N A for FAST kinase 
chromosome 4 open reading frame 9 (C4orf9), m R N A 
likely ortholog of mouse 5-azacytidine induced gene 1 
(AZI1), m R N A 
KIAA0565 gene product (KIAA0565), m R N A 
hypothetical protein FLJ10211 (FLJ10211), m R N A 
likely homolog of rat kinase D-interacting substance of 220 
kDa (KIDINS220), m R N A 
KIAA0303 protein (KIAA0303), m R N A 
formin homology 2 domain containing 3 (FHOD3), m R N A 
myosin V B (MY05B), m R N A 
















chromosome 6 open reading frame 110 (C6orfll0), m R N A 
similar to FLJ46354 protein (LOC389690), m R N A 
similar to KIAA1691 protein (LOC392619), m R N A 
hypothetical gene supported by AK126104; BX648733 
(LOC401024), m R N A 
similar to RIKEN c D N A 9330128H10 gene (LOC401323), 
m R N A 
similar to RIKEN c D N A 9330128H10 gene (LOC401323), 
m R N A 
similar to hypothetical protein (LOC402354), m R N A 
similar to RIKEN c D N A 9330128H10 gene (LOC402479), 
m R N A 
similar to RIKEN c D N A 9330128H10 gene (LOC402479), 
m R N A 
m R N A for soluble guanylyl cyclase 
m R N A for soluble guanylyl cyclase 
m R N A for K E T protein 
m R N A for SLC7A8 protein 
m R N A for ankyrin B (440 kDa) 
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A P P E N D I X C 
LIST OF MOUSE TARGET GENES PREDICTED BY NTHunter 
( F R O M C H A P T E R 5) 
GenBank ID 

























Mporc-d m R N A for porcupine-D, complete cds 
brain cDNA, clone MNCb-3763, similar to AC004410 
fos39554_l (Homo sapiens) 
m R N A for RA175, complete cds 
non-erythrocyte beta spectrin m R N A , complete cds 
TA*p63 alpha m R N A , complete cds 
interleukin enhancer binding factor 3 (Ilf3) m R N A , 
complete cds 
bright and dead ringer gene product homologous protein 
Bdp m R N A , complete cds 
unconventional myosin-15 m R N A , complete cds 
m u opioid receptor variant F m R N A , complete cds 
m u opioid receptor variant F m R N A , complete cds 
peroxisomal Nl-acetyl-spermine 
betaPix-b m R N A , complete cds 
prostaglandin transporter P G T m R N A , complete cds 
cell recognition molecule CASPR4 m R N A , complete cds 
Rab6-interacting protein 2 isoform A m R N A , complete cds 
Rab6-interacting protein 2 isoform B m R N A , complete cds 
actin-binding protein frabin-alpha m R N A , complete cds 
putative R N A methylase m R N A , complete cds 
S6 kinase 2 
S6 kinase 2 
m R N A for 53BP1 protein 
ES cells cDNA, RIKEN full-length enriched library, 
clone:2410075D05 product:hypothetical N-6 Adenine-
specific D N A methylase containing protein, full insert 
sequence 
10 days neonate skin cDNA, RIKEN full-length enriched 
library, clone:4732465J15 product:weakly similar to N-
ACETYLGLUCOSAMINE-6-SULFATASE[Coturnix 

















adult male testis cDNA, RIKEN full-length enriched library, 
clone:4931410H15 producthypothetical protein, full insert 
sequence 
6 days neonate head cDNA, RIKEN full-length enriched 
library, clone:5430412B19 producthypothetical Amine 
oxidase containing protein, full insert sequence 
adult male diencephalon cDNA, RIKEN full-length 
enriched library, clone:9330168O12 product:weakly similar 
to DJ846F13.1 ( P H O S P H A T I D E ACID P H O S P H A T A S E 
TYPE 2C) ( F R A G M E N T ) 
12 days embryo embryonic body between diaphragm 
region and neck cDNA, RIKEN full-length enriched library, 
clone:9430027K19 product:weakly similar to N-
ACETYLGLUCOSAMINE-6-SULFATASE 
adult male bone cDNA, RIKEN full-length enriched library, 
clone:9830162M14 product:weakly similar to N-
ACETYLGLUCOSAMINE-6-SULFATASE 
16 days neonate thymus cDNA, RIKEN full-length enriched 
library, clone:A130052K22 productimmunoglobulin heavy 
chain 6 (heavy chain of IgM), full insert sequence 
adult male hypothalamus cDNA, RIKEN full-length 
enriched library, clone: A230072B04 producthypothetical 
protein, full insert sequence 
adult male hypothalamus cDNA, RIKEN full-length 
enriched library, clone:A230103M05 product:calcitonin 
receptor, full insert sequence 
3 days neonate thymus cDNA, RIKEN full-length enriched 
library, clone:A630034L20 productweakly similar to FC 
RECEPTOR-LIKE PROTEIN 1 
3 days neonate thymus cDNA, RIKEN full-length enriched 
library, clone: A630088O16 product:similar to 
D A C H S H U N D - L I K E PROTEIN D A C H 2 
adult male corpora quadrigemina cDNA, RIKEN full-
length enriched library, clone:B230363K08 
producthypothetical PapD-like structure containing 
protein 
8 days embryo whole body cDNA, RIKEN full-length 
enriched library, clone:5730523J24 product:PP1201 
PROTEIN homolog 
16 days embryo head cDNA, RIKEN full-length enriched 
library, clone:C130058L07 product:weakly similar to N-
ACETYLGLUCOSAMINE-6-SULFATASE 
16 days embryo head cDNA, RIKEN full-length enriched 
library, clone:C130083H12 producthypothetical 
Phospholipid and glycerol acyltransferase (from 
'motifs_6.msf') and EF-hand containing protein 
0 day neonate lung cDNA, RIKEN full-length enriched 
library, clone:E030047P06 product:solute carrier family 21 

























0 day neonate eyeball cDNA, RIKEN full-length enriched 
library, clone:E130118N02 product:weakly similar to 
DJ846F13.1 ( P H O S P H A T I D E ACID P H O S P H A T A S E 
TYPE 2C) ( F R A G M E N T ) 
kidney CCL-142 R A G cDNA, RIKEN full-length enriched 
library, clone:G430107K15 productribosomal protein S6 
kinase, 70kD, polypeptide 2 
kidney CCL-142 R A G cDNA, RIKEN full-length enriched 
library, clone:G430107K15 productribosomal protein S6 
kinase, 70kD, polypeptide 2 
m R N A for mKIAA0587 protein 
m R N A for mKIAA0587 protein 
m R N A for mKIAA0595 protein 
m R N A for mKIAA1219 protein 
m R N A for mKIAA1250 protein 
m R N A for mKIAA1247 protein 
RPGR-interacting protein m R N A , complete cds 
C C A A T displacement protein C D P (Cutll) m R N A , 
complete cds 
C C A A T displacement protein C D P (Cutll) m R N A , 
complete cds 
phosphatidylinositol-binding clathrin assembly protein 
(Picalm) m R N A , complete cds 
betaPix-bL m R N A , complete cds 
zona pellucida binding protein 2 (Zpbp2) m R N A , complete 
cds 
potassium voltage-gated channel major isoform 1 (Kcnql) 
m R N A , complete cds 
BB610056 RIKEN full-length enriched, adult male liver M u s 
musculus c D N A clone 1300006B11 5', m R N A sequence 
phosphatidylinositol binding clathrin assembly protein, 
m R N A (cDNA clone MGC:19382 IMAGE:2651109), 
complete cds 
contactin associated protein 4, m R N A (cDNA clone 
M G G 3 6 5 1 9 IMAGE:5369648), complete cds 
potassium voltage-gated channel, subfamily Q, member 1, 
m R N A (cDNA clone M G G 5 4 7 0 2 IMAGE:6314642), 
complete cds 
ATPase, H + transporting, lysosomal VO subunit A isoform 
4, m R N A (cDNA clone M G G 5 4 8 2 4 IMAGE:6315485), 
complete cds 
RIKEN c D N A 9330174J19 gene, m R N A (cDNA clone 
MGC:57080 IMAGE:6486835), complete cds 














RIKEN c D N A 1700017D11 gene, m R N A (cDNA clone 
IMAGE:6772587) 
ribosomal protein S6 kinase, polypeptide 2, m R N A (cDNA 
clone IMAGE:6331314), complete cds 
ribosomal protein S6 kinase, polypeptide 2, m R N A (cDNA 
clone IMAGE:6331314), complete cds 
c D N A clone MGC:62428 IMAGE:5687835, complete cds 
S U M O 
catenin src, m R N A (cDNA clone MGC:62385 
IMAGE:6408956), complete cds 
c D N A sequence BC006909, m R N A (cDNA clone 
M G G 6 2 6 7 2 IMAGE:6310272), complete cds 
potassium voltage-gated channel, subfamily Q, member 1, 
m R N A (cDNA clone M G G 6 2 6 4 2 IMAGE:6397978), 
complete cds 
c D N A clone M G G 6 7 7 8 0 IMAGE.3599941, complete cds 
oxoglutarate dehydrogenase (lipoamide), m R N A (cDNA 
clone M G G 6 7 1 9 3 IMAGE:6827509), complete cds 
c D N A clone MGC:67710 IMAGE:6395070, complete cds 












G N A S (guanine nucleotide binding protein, alpha 
stimulating) complex locus, m R N A (cDNA clone 
IMAGE:6822390), complete cds 
sulfatase 2, m R N A (cDNA clone MGC:86096 
IMAGE:6810085), complete cds 
guanine nucleotide binding protein, alpha inhibiting 2, 
m R N A (cDNA clone M G G 9 0 1 0 2 IMAGE.5717305), 
complete cds 
peroxisome proliferative activated receptor, gamma, 
coactivator-related 1, m R N A (cDNA clone M G G 9 0 1 3 3 
IMAGE:6825158), complete cds 
RIKEN c D N A E030049G20 gene, m R N A (cDNA clone 
M G G 9 0 0 7 6 IMAGE:6856184), complete cds 
c D N A sequence BC005662, m R N A (cDNA clone 
M G G 7 6 5 1 9 IMAGE:30475544), complete cds 
expressed sequence All 18078, m R N A (cDNA clone 
M G G 9 2 9 7 2 IMAGE:6835202), complete cds 
c D N A clone M G G 7 8 0 1 4 IMAGE:4196478, complete cds 
602798514F1 N C I _ C G A P _ M a m 4 M u s musculus c D N A 
clone IMAGE:4919571 5', m R N A sequence 
AGENCOURT_6419456 NCI_CGAP_Ov44 M u s musculus 
c D N A clone IMAGE:5504484 5', m R N A sequence 
mai76g07.yl McCarrey Eddy spermatocytes M u s musculus 




























N M 023638.3 
UI-M-HD0-ckp-a-06-0-UI.rl N I H _ B M A P _ H D 0 M u s 
musculus c D N A clone IMAGE:30612005 5', m R N A 
sequence 
E0483D06-5 NIA Mouse E11.5 whole embryo c D N A library 
(Long) M u s musculus c D N A clone NIA:E0483D06 
IMAGE:30876521 5', m R N A sequence 
E0489A01-5 N I A Mouse E11.5 whole embryo c D N A library 
(Long) M u s musculus c D N A clone NIA:E0489A01 
IMAGE:30877056 5', m R N A sequence 
m R N A for proteoglycan, PG-M. 
m R N A for proteoglycan, PG-M. 
m R N A for Ftp-1, complete cds. 
m R N A for Ftp-1, complete cds. 
macrophage scavenger receptor type II m R N A , complete 
cds. 
Mouse myocyte nuclear factor (MNF) m R N A , complete 
cds. 
calcitonin receptor (Calcr), m R N A 
guanine nucleotide binding protein, alpha inhibiting 2 
(Gnai2), m R N A 
potassium voltage-gated channel, subfamily Q, member 1 
(Kcnql), m R N A 
spectrin beta 2 (Spnb2), transcript variant 2, m R N A 
cut-like 1 (Drosophila) (Cutll), transcript variant 1, m R N A 
cut-like 1 (Drosophila) (Cutll), transcript variant 1, m R N A 
interleukin enhancer binding factor 3 (Ilf3), m R N A 
lymphoid enhancer binding factor 1 (Lefl), m R N A 
myosin X V (Myol5), transcript variant 1, m R N A 
protein tyrosine phosphatase, receptor type, U (Ptpru), 
m R N A 
protein tyrosine phosphatase, receptor type, U (Ptpru), 
m R N A 
transcriptional regulator, SIN3A (yeast) (Sin3a), m R N A 
transformation related protein 53 binding protein 1 
(Trp53bpl), m R N A 
A T rich interactive domain 3B (Bright like) (Arid3b), 
m R N A 
ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), 
m R N A 
ribosomal protein S6 kinase, polypeptide 2 (Rps6kb2), 
m R N A 
RIKEN c D N A 2010106G01 gene (2010106G01Rik), m R N A 
porcupine homolog (Drosophila) (Porcn), transcript variant 































X M 139336.4 
retinitis pigmentosa GTPase regulator interacting protein 1 
(Rpgripl), m R N A 
RIKEN c D N A 1700017D11 gene (1700017DllRik), 
transcript variant 1, m R N A 
RIKEN c D N A 2310061B02 gene (2310061B02Rik), m R N A 
RIKEN c D N A 2410075D05 gene (2410075D05Rik), m R N A 
macrophage scavenger receptor 1 (Msrl), m R N A 
solute carrier organic anion transporter family, member 2al 
(Slco2al), m R N A 
Rab6 interacting protein 2 (Rab6ip2), m R N A 
contactin associated protein 4 (Cntnap4), m R N A 
FYVE, RhoGEF and P H domain containing 4 (Fgd4), 
m R N A 
c D N A sequence BC005662 (BC005662), m R N A 
c D N A sequence BC006909 (BC006909), m R N A 
S U M O 
phosphatidylinositol binding clathrin assembly protein 
(Picalm), m R N A 
polyamine oxidase (Paox), m R N A 
RIKEN c D N A 9330174J19 gene (9330174J19Rik), m R N A 
RIKEN c D N A B230363K08 gene (B230363K08Rik), m R N A 
forkhead box KI (Foxkl), transcript variant 1, m R N A 
immunoglobulin superfamily, member 4A (Igsf4a), 
transcript variant 1, m R N A 
calcitonin receptor lb m R N A , complete cds. 
kidney-specific Na-K-Cl cotransport protein splice isoform 
F (NKCC2) m R N A , complete cds. 
mSin3A (sin3A) m R N A , complete cds. 
receptor protein tyrosine phosphatase-lamda (ptp-lambda) 
m R N A , complete cds. 
receptor protein tyrosine phosphatase-lamda (ptp-lambda) 
m R N A , complete cds. 
potassium channel subunit (KvLQTl) m R N A , complete 
cds. 
Mouse LEF1 m R N A for lymphoid enhancer binding factor 
1 
discs, large homolog 5 (Drosophila) (Dlg5), m R N A 
hypothetical protein LOC213109 (LOC213109), m R N A 
RIKEN c D N A 4933421B21 gene (4933421B21Rik), m R N A 
hypothetical protein A530054K11 (A530054K11), m R N A 
similar to putative pheromone receptor (LOC223385), 
m R N A 
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XM_140451.11 laminin, alpha 3 (Lama3), m R N A 
XM_146954.16 similar to Myosin Vc (Myosin 5C) (LOC208943), m R N A 
XM_148343.3 similar to Putative Rho 
XM_284502.5 SUMO-1-specific protease (Suspl-pending), m R N A 
XM_358923.3 similar to RIKEN c D N A 1810036124 (LOC385719), m R N A 
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A P P E N D I X D 
LIST OF RAT TARGET GENES PREDICTED BY NTHunter 
(FROM CHAPTER 5) 
GenBank ID 






















KIDINS220 (Kidins220) m R N A , complete cds 
m R N A for collybistin I 
m R N A for cyclic nucleotide-gated channel 2b 
m R N A for G A B A - A receptor interacting factor-1 (GRIF-1 
gene), splice variants 
partial m R N A for M H C class lb antigen (rtl-E2d gene), 
allele E2d(c) 
Abl-346 m R N A , complete cds 
Cc2-5 m R N A , complete cds 
rhotekin isoform 1 m R N A , complete cds; alternatively 
spliced 
Kv4 potassium channel auxiliary subunit m R N A , complete 
cds 
AMGNNUGNRHY5-00391-B3-A W Rat hypothalamus 
(10471) Rattus norvegicus c D N A clone nrhy5-00391-b3 5', 
m R N A sequence 
hultzomica01408 Rat lung airway and parenchyma c D N A 
libraries Rattus norvegicus c D N A clone Contigl074 5', 
m R N A sequence 
F32G05_035.abl.R Rat retinal ganglion cell Rattus 
norvegicus cDNA, m R N A sequence 
AGENCOURT_26621744 NIH_MGC_253 Rattus norvegicus 
c D N A clone IMAGE:7302753 5', m R N A sequence 
Rattus norvegicus Clb receptor m R N A , complete cds 
transformation related protein 63 (Trp63), m R N A 
collybistin I (Arhgef9), m R N A 
tumor protein p53 (Tp53), m R N A 
purinergic receptor P2X ligand-gated ion channel, 3 (P2rx3), 
m R N A 
kinase D-interacting substance of 220 kDa (Kidins220), 
m R N A 
















rhotekin (Rtkn), m R N A 
amelogenin m R N A , complete cds 
nuclear oncoprotein p53 
m R N A for P2X3 receptor 
GRP1 binding protein GRSP1 (Grspl), m R N A 
myomesin 1 (Myoml), m R N A 
similar to harmonin isoform b3 (LOC308596), m R N A 
E2F transcription factor 5 (E2f5), m R N A 
similar to RA175 (LOC363058), m R N A 
neogenin (Neol), m R N A 
similar to cystic fibrosis transmembrane conductance 
regulator (LOC368064), m R N A 
cystic fibrosis transmembrane conductance regulator 
homolog (Cftr), m R N A 
m R N A for T A 2 K E T alpha protein (p63 gene) 
m R N A for P2X2 receptor, splice variant P2X2b 
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A P P E N D I X E 
AutoDB DATABASE BUILDING PROCESS 
( F R O M C H A P T E R 7) 
General information about the directory structure: 
Note: All build steps assume you are using the Bash shell. STDERR and 
S T D O U T redirect work differently for other shells, such as csh; please check 
to make sure you use the appropriate redirects for your shell. 
The root directory for all input data and building tools for AutoDB is 
/projects/AutoDB. 
The /projects/AutoDB/InputData directory contains data directories for 
each organism and database version. Create a new organism directory and 
database version directory for each new AutoDB project, if necessary, and 
then create the ExpressedSequence and GenomicSequence directories. 
The GenomicSequence directory contains symbolic links to the genomic 
chromosomal sequence data files (in the directories 
/seqdata/genomes/<organism>/<chromosome_directory>), plus 
the nibs directory for the B L A T . nib files (see step 1-A below) and the 
str directory for the stripped data files (see step 1-B below). 
T h e 6 steps required for running A u t o D B a n d building the w e b 
interface: 
Step 1: Preparing Genomic Data 
Note: The Genome Sequence Administrator should perform the first two 
data preparation steps, since not everyone has permission to write to the 
/seqdata genome sequence repository. 
The genome sequence files for the organism should be downloaded from the 
source and placed in: 
/seqdata/genomes/<organism>/<genome_version> 
191 
The GenomicSequence directory of the new AutoDB project should be set 
up as a symbolic link to the sequence data directory. The genome data 
directory /seqdata/genomes/<organism>/<genome_version> should 
then be set up to contain the /nibs and /str directories detailed in the 
following steps. 
(A) .nib files have to be generated for B L A T from the FASTA genome 
sequence files in the genome data directory. To create . nib files use BLAT's 
FaToNib tool, /usr/local/biotools/blat/FaToNib. 
Method: 
$ cd /projects/AutoDB/InputData/<organism>/<DB_NAME>/ 
GenomicSequence 
$ mkdir nibs 
$ /usr/local/biotools/blat/faToNib chrl.fa nibs/chrl.nib 
Repeat for each FASTA chromosome sequence file. 
Note: The directory GenomicSequence above is a symbolic link to 
/seqdata/genomes/<organism>/<genome_version>, which has 
limited write permission, so an authorized administrator must perform these 
steps. 
(B) .str files need to be created for the genomic sequence data as follows. 
These are stripped data files, where the > identifier line and all whitespace 
are removed from the genomic F A S T A file. From directory 
/projects/AutoDB/build/bin, run format-str-files.pi. 
Method: 
$ mkdir /seqdata/genomes/<organism>/<genome_version>/str 






ce/str/ -p 'chr.*\.fa' 
Note: Again, the directory GenomicSequence above is a symbolic link to 
/seqdata/genomes/<organism>/<genome_version>. 
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(C) For each organism, .ini configuration files should be checked. These files 
are named after the organisms, and are placed in 
/projects/AutoDB/build/conf. Before each run, these files need to be 
checked and updated. The fields in this file are as follows: 
1. Blat: This specifies the path to the blat gfClient. Probably does not 
need to be changed. 
2. nibs_dir: Path to the nibs files used for the particular run. This will 
likely need to be updated with each new version of the organism's 
database. 
3. hosts_ports: This is a list of the hosts and port numbers on which 
gfServers for this organism are running. Each entry consists of a host 
name and port number, separated by a single colon. Multiple entries are 
separated by three colons. 
Example: 
hosts_ports=HOST: 1777 7 -This entry is for one host/port. 
hosts_ports=HOSTl:17777:::H0ST1:17778:::H0ST2:17777: : 
HOST2:17778 - This entry lists four gfServers across two different 
hosts. 
4. genome_data: Full path to the str directory. Example: 
genome_data=/projects/AutoDB/InputData/mouse/MouSDB5/ 
GenomicSequence/str/ 
5. chr_ids: single-colon separated list of chromosome ids. Must match 
the str and nibs file names, without their extensions. Example: 
chr_ids=chr1:chr2:chr3:chr4 
6. min_trans_per_clust: Minimum transcripts per cluster. Default is 
3, which eliminates singleton and doubleton clusters. 
7. percent_coverage: Minimum percent ID that a transcript must have 
to the genome else it will be discarded. Default is 75. 
8. exon_percent_coverage: Minimum percent ID of each exon to the 
genome, else the transcript is discarded. If the exon has percent ID less 
than this number, it may still be considered if it passes based on 
mm_threshold. Default is 95. 
9. mm_threshold: M a x i m u m amount of mismatches an exon can have if 
it fails exon_percent_coverage. This allows small exons which may have 
a low percent ID but also low number of mismatches to still be 
considered valid. Default is 5. 
10. min_exons: minimum number of exons that a transcript must have to 
be included in the database. Since AutoDB analyzes splice variation, the 
default for this option is 2 (2 or more exons are required to have splice 
sites). 
11. min_exons_est and est_regex can be disregarded as they are not 
currently used. 
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Step 2: Running Blat 
The file /projects/AutoDB/gfServers lists each organism 
followed by one or more host names and one or more port numbers. This is 
to help distribute hosts and ports across all organisms, to prevent running all 
organisms on one server, on one port. If your organism is not listed, please 
add it to the end of the file and take the next port number (i.e. if the highest 
port number in the file that has been used is 17789, please use 17790). 
To start the gfServer(s), first ssh into the host you need to run it on, then 
navigate to the nibs file directory: 
$ cd /projects/AutoDB/InputData/<organism>/<DB_NAME>/ 
GenomicSequence/nibs 
While in the nibs directory, run: 
$ /usr/local/biotools/blat/gfServer start <hostname> 
<port_number> *.nib & 
Then log out of the host. 
Important: Before going on to the next step, it is vital that you double-check 
the availability of the gfServer(s) you started. To do so run the following 
command for each host/port combination. 
$ /usr/local/biotools/blat/gfServer status <hostname> 
<port_number> 
If the server is available it will return with multiple lines of information. If 
not, it will state that it cannot connect to the server. 
Step 3: Starting AutoDB 
From the directory /projects/AutoDB/build/bin, run 
generate-project-data.pl, providing transcript input data from 
ExpressedSequence directory. Following command shows starting 
AutoDB for a Drosophila melanogaster database. 
$ ./generate-project-data.pl —p DmelSDB —o dmelanogaster 
—data 
/projects/AutoDB/InputData/dmelanogaster/DmelSDB/Expresse 
dSequence/Dmelanogaster-20050315.gbank > DmelSDB.err 2>&1 
& 
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Note: If you have multiple data files, please pass multiple -data arguments 
to generate-project-data.pl. The -data option is used for GenBank, 
UniGene, dbEST and Ensembl formats. The files must end in.gbank, 
.ugn, .dbest or.embl respectively. 
Step 4: Loading information into databases 
After the first three steps are complete, information is loaded into 
databases with the following script. From the directory 
/projects/AutoDB/build/bin, run project-step2 .pi. For each run, 
the database version number (dbver) should be updated. Following 
command shows loading information into a Drosophila melanogaster database. 
$ ./project-step2.pi —p DmelSDB —o dmelanogaster —abbrev 
Dm -dbver 1 > DmelSDB.step2.err 2>&1 & 
Step 5: Stopping Blat 
After the runs are done, it is important to stop the gfServer with the 
following command. This frees the resources that the gfServer(s) were using. 
$ /usr/local/biotools/blat/gfServer stop <hostname> 
<port_number> 
Step 6: Creating the web interface 
After the SDB is created and populated, run the following command: 
$ /projects/AutoDB/www/createPhpInterface <NewSDB> <user> 
<hostname> <schema> 
Example: 
$ /projects/AutoDB/www/createPhpInterface DmelSDB anovo 
emmy 3 
Note: Variable <schema> refers to the SDB schema, which has changed to its 
current state after HumanSDB2. All SDBs starting from HumanSDB3, 
MouSDB5, and RatSDB2 have schema version 3. 
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<NewSDB> <user> <host> 
/projects/AutoDB/www/CHECK_VAR_CLUSTERS.pl <NewSDB> 
<user> <host> 
/projects/AutoDB/www/CREATE_STATS.pl <NewSDB> <user> 
<host> <schema> 




The list of AutoDB databases is accessible through the following URL: 
http:/ /sgc.ucsd.edu/autodb/sdb.php. 
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